ћед”нивер - MedUniver.com ¬се разделы сайта ¬идео по медицине  ниги по медицине ‘орум консультаций врачей  
–екомендуем:
ѕедиатри€:
ѕедиатри€
√енетика в педиатрии
ƒетска€ аллергологи€ и иммунологи€
ƒетска€ гастроэнтерологи€
ƒетска€ гематологи€
ƒетска€ гинекологи€
ƒетска€ и подросткова€ стоматологи€
ƒетска€ кардиологи€
ƒетска€ неврологи€
ƒетска€ нефрологи€
ƒетска€ онкологи€
ƒетска€ пульмонологи€
ƒетска€ ревматологи€
ƒетска€ урологи€
ƒетска€ фармакологи€
ƒетска€ эндокринологи€
»нфекционные болезни у детей
Ќеонатологи€
Ќеотложные состо€ни€ детей
ѕодросткова€ медицина
–ост и развитие ребенка
ќрганизаци€ педиатрической помощи
‘орум
 

јвторы трудов (статей) использованные при подготовке материалов по детской гематологии в педиатрии

¬ стать€х на сайте использованы следующие сокращени€:

  • ∞F Ч температура по ‘аренгейту
  • ∞C Ч температура по ÷ельсию
  • 5-Ќ“ Ч 5-гидроксииндолуксусна€ кислота мочи
  • јЅ Ч антибиотик(и)
  • јЅЋј Ч аллергический бронхолегочный аспергиллез
  • јЅ“ Ч антибактериальна€ терапи€
  • ј¬ Ч атриовентрикул€рный
  • ј√ Ч артериальна€ гипертензи€
  • ј√н Ч антиген
  • јƒ Ч артериальное давление
  • јƒ√ Ч антидиуретический гормон
  • јƒ— Ч анатоксин дифтерийно-столбн€чный
  • јƒ—-ћ Ч анатоксин дифтерийно-столбн€чный (малые дозы)
  • јƒ‘ Ч аденозиндифосфорна€ кислота, аденозиндифосфат
  • ј ƒ— Ч анатоксин коклюшно-дифтерийно-столбн€чный
  • ј “√ Ч адренокортикотропный гормон
  • ј Ў Ч аортокоронарное шунтирование
  • јЋ“ Ч аланинаминотрансфераза
  • амер. Ч американский
  • јћ  Ч азот мочевины крови
  • јћ‘ Ч аденозинмонофосфорна€ кислота, аденозинмонофосфат
  • јЌј Ч антинуклеарные антитела
  • анат. Ч анатомический
  • англ. Ч английский
  • јѕ‘ Ч ангиотензин-превращающий фермент
  • ј–¬“ Ч антиретровирусна€ терапи€
  • ј–ѕ Ч активность ренина в плазме крови
  • ACT Ч аспартатаминотрансфераза
  • ј“л Ч антитело
  • ј“‘ Ч аденозинтрифосфорна€ кислота, аденозинтрифосфат
  • јуƒ Ч аутосомно-доминантный
  • ју– Ч аутосомно-рецессивный
  • ј‘ѕ Ч α-фетопротеин
  • ј‘— Ч антифосфолипидный синдром
  • ј’Ё Ч ацетилхолинэстераза
  • ј÷’ Ч ацетилхолин
  • ј„“¬ Ч активированное частичное тромбопластиновое врем€
  • Ѕј Ч бронхиальна€ астма
  • Ѕјƒ Ч биологически активна€ добавка
  • ЅјЋ Ч бронхоальвеол€рный лаваж
  • Ѕј– Ч бипол€рное аффективное расстройство (I или II типа)
  • Ѕ   Ч большой круг кровообращени€
  • ЅЋƒ Ч бронхолегочна€ дисплази€
  • ЅЋЌѕ√ Ч блокада левой ножки пучка √иса
  • Ѕћ—Ё Ч бюро медико-социальной экспертизы
  • Ѕѕ Ч брюшна€ полость
  • ЅѕЌѕ√ Ч блокада правой ножки пучка √иса
  • Ѕ–ћ Ч базовые реанимационные меропри€ти€
  • Ѕ–Ќ— Ч быстро разрешившеес€ необъ€снимое событие
  • Ѕ÷∆ Ч бацилла  альметта-√ерена в т.ч. Ч в том числе
  • Ѕ‘ѕ - биофизический профиль плода
  • в. Ч век
  • в/ Ч внутри... в сложносоставных словах (напр. в/сосудистый, в/черепной и т.п.)
  • в/а Ч внутриартериально
  • в/в Ч внутривенно
  • в/к Ч внутрикожно
  • в/м Ч внутримышечно
  • вв. Ч века
  • в-во Ч вещество
  • ¬¬Ё Ч военно-врачебна€ экспертиза
  • ¬√ƒ Ч внутриглазное давление
  • ¬√„ Ч вирус герпеса человека
  • ¬ƒѕ Ч верхние дыхательные пути
  • ¬∆  Ч внутрижелудочковое кровоизли€ние
  • ¬«  Ч воспалительные заболевани€ кишечника
  • ¬«ќћ“Чвоспалительные заболевани€ органов малого таза
  • ¬»ѕ Ч вазоактивный интестинальный пептид
  • ¬»„ Ч вирус иммунодефицита человека
  • ¬ћѕ Ч высокотехнологична€ медицинска€ помощь
  • ¬ћ— Ч внутриматочное средство (спираль)
  • ¬Ќ Ч вирусна€ нагрузка
  • ¬Ќ— Ч вегетативна€ нервна€ система
  • ¬ќ¬ Ч ¬елика€ ќтечественна€ война
  • ¬ќ√ћ Ч высокогорный отек головного мозга
  • ¬ќ« Ч ¬семирна€ организаци€ здравоохранени€
  • ¬ќЋ Ч высокогорный отек легких
  • ¬ќћ  Ч врач, осуществл€ющий медицинский контроль
  • ¬ќѕ Ч врач общей практики
  • ¬ѕ¬ Ч верхн€€ пола€ вена
  • ¬ѕ√ Ч вирус простого герпеса
  • ¬ѕ– Ч врожденные пороки развити€
  • ¬ѕ— Ч врожденный порок сердца
  • ¬ѕ„ Ч вирус папилломы человека
  • ¬–“ Ч вспомогательные репродуктивные технологии
  • ¬—ќ Ч водно-солевой обмен
  • ¬„ƒ Ч внутричерепное давление
  • ¬„»¬Ћ Ч высокочастотна€ искусственна€ вентил€ци€ легких (HFV)
  • ¬ЁЅ Ч вирус Ёпштейна-Ѕарр
  • г Ч грамм
  • г. Ч год
  • √-6-‘ƒ Ч глюкозо-6-фосфатдегидрогеназа
  • √јћ  Ч гамма-аминомасл€на€ кислота
  • √Ѕ Ч гипертоническа€ болезнь
  • √ЅЌ Ч гемолитическа€ болезнь новорожденного
  • √Ѕќ Ч гипербарическа€ оксигенаци€
  • √«“ Ч гиперчувствительность замедленного типа
  • гист. Ч гистологический
  • √  Ч грудна€ клетка
  • √ ћѕ Ч гипертрофическа€ кардиомиопати€
  • √ — Ч глюкокортикостероид(ы)
  • √Ћ√ Ч гемофагоцитарный лимфогистиоцитоз
  • √Ћѕ— Ч геморрагическа€ лихорадка с почечным синдромом
  • √ћ Ч головной мозг
  • √ћ- —‘ Ч гранулоцитарно-макрофагальный колониестимулирующий фактор
  • √ћ‘ Ч гуанозинмонофосфат
  • √н–√ Ч гонадотропин-рилизинг-гормон
  • √Ќ“ Ч гиперчувствительность немедленного типа
  • √ѕќƒ Ч грыжа пищеводного отверсти€ диафрагмы
  • √–ƒ— Ч гипоксическа€ реакци€ дыхательной системы греч. Ч греческий
  • √“‘ Ч гуанозинтрифосфат
  • √”— Ч гемолитико-уремический синдром
  • √ц Ч герц
  • √ЁЅ Ч гематоэнцефалический барьер
  • √Ё– Ч гастроэзофагеальный рефлюкс
  • √Ё–Ѕ Ч гастроэзофагеальна€ рефлюксна€ болезнь
  • дЅ Ч децибел
  • ƒ¬— Ч диссеминированное внутрисосудистое свертывание
  • ƒ√“ Ч дигидротестостерон
  • ƒƒ Ч дифференциальна€ диагностика, дифференциально-диагностический
  • ƒƒЅј Ч длительнодействующие β2-агонисты
  • ƒƒ  Ч дифференциально-диагностический критерий (критерии)
  • ƒƒ–ћ - допустимый диапазон распределени€ макронутриентов
  • ƒ» Ч доверительный интервал
  • ƒ  Ч диагностический критерий
  • ƒ ј Ч диабетический кетоацидоз
  • ƒ ћѕ Ч дилатационна€ кардиомиопати€
  • ƒћ∆ѕ Ч дефект межжелудочковой перегородки
  • ƒћѕѕ Ч дефект межпредсердной перегородки
  • ƒћ— Ч добровольное медицинское страхование
  • ƒЌ Ч дыхательна€ недостаточность
  • ƒЌ  Ч дезоксирибонуклеинова€ кислота
  • ƒЌ“ Ч дефекты нервной трубки
  • ƒќ - дыхательный объем
  • ƒќ‘ј Ч дигидроксифенилаланин
  • ƒѕ Ч дыхательные пути
  • ƒѕ  Ч двенадцатиперстна€ кишка
  • ƒѕћ Ч дата последней менструации
  • ƒѕѕ - допустимый предел потреблени€
  • др. Ч другие
  • ƒ“ѕ Ч дорожно-транспортное происшествие
  • ƒ÷ѕ Ч детский церебральный паралич
  • ≈ƒ Ч единица действи€, единица
  • ∆¬ѕ Ч желчевывод€щие пути
  • ∆ƒј Ч железодефицитна€ анеми€
  • ∆≈Ћ Ч жизненна€ емкость легких
  • ∆ Ѕ Ч желчекаменна€ болезнь
  • ∆   Ч желудочно-кишечное кровотечение
  • ∆ “ Ч желудочно-кишечный тракт
  • ∆Ќ¬Ћѕ Ч жизненно необходимые и важные лекарственные препараты (список, перечень)
  • «¬”– Ч задержка внутриутробного развити€
  • «Ћ Ч здоровые люди (лица)
  • «Ќќ Ч злокачественное новообразование
  • «ќ Ч здравоохранение
  • «ќ∆ Ч здоровый образ жизни
  • «—Ќ Ч застойна€ сердечна€ недостаточность
  • ијѕ‘ Ч ингибиторы ангиотензин-превращающего фермента
  • »Ѕ— Ч ишемическа€ болезнь сердца
  • »¬Ћ Ч искусственна€ вентил€ци€ легких
  • »√ — Ч ингал€ционные глюкокортикостероиды
  • »«Ћ Ч интерстициальные заболевани€ легких
  • » ѕ Ч иммунокомпрометированные пациенты
  • »Ћ Ч интерлейкин
  • »ЋƒЅ Ч интегрированное лечение детских болезней
  • »ћ Ч инфаркт миокарда
  • »ћјќ Ч ингибитор(ы) моноаминоксидазы
  • »ћбпЅ“ Ч инфаркт миокарда без подъема сегмента ST
  • »ћѕ Ч инфекци€ мочевых (мочевывод€щих) путей
  • »ћп«“ Ч инфаркт миокарда с подъемом сегмента
  • ST »ћ“ Ч индекс массы тела
  • »ќЋ Ч интраокул€рна€ линза
  • »ѕѕ Ч ингибиторы протонной помпы (протонного насоса)
  • »ѕѕѕ Ч инфекции, передаваемые половым путем
  • »—— Ч индивидуальные спасательные средства истор. Ч историческое итал. Ч италь€нский
  • »“ѕ Ч идиопатическа€ тромбоцитопеническа€ пурпура
  • »“Ў Ч инфекционно-токсический шок »‘ј Ч иммуноферментный анализ
  •  ј Ч коронарна€(ые) артери€(и)
  • к¬ Ч киловольт
  • кг Ч килограмм
  •  ƒЅј Ч короткодействующие β2-агонисты
  •  ƒƒ Ч конечно-диастолическое давление
  •  ƒќ Ч конечно-диастолический объем
  •  ƒ– Ч конечно-диастолический размер
  • кит. Ч китайский
  • ккал Ч килокалори€
  • кл. Ч клетки, клеток
  •  ћѕ Ч качество медицинской помощи
  •  ој Ч коэнзим ј, кофермент ј
  •  ќ≈ Ч колониеобразующа€ единица
  •  ќ  Ч комбинированные оральные контрацептивы
  •  ѕ“ Ч когнитивно-поведенческа€ терапи€
  •  – Ч клинические рекомендации
  •  —ƒ Ч конечно-систолическое давление
  •  —ќ Ч конечно-систолический объем
  •  —– Ч конечно-систолический размер
  •  “ Ч компьютерна€ томографи€
  •  “¬– Ч компьютерна€ томографи€ высокого разрешени€
  •  “√ Ч кардиотокографи€
  •  ‘  Ч креатинфосфокиназа
  •  ў— Ч кислотно-щелочное состо€ние
  • л Ч литр
  • л/о Ч ложноотрицательный
  • л/п Ч ложноположительный
  • Ћј Ч легочна€ артери€
  • лат. Ч латинский
  • Ћ√ Ч лютеинизирующий гормон
  • Ћƒ√ Ч лактатдегидрогеназа
  • Ћ∆ Ч левый желудочек
  • Ћќ– Ч имеющий отношение к оториноларингологии (Ћќ–-врач, Ћќ–-органы)
  • Ћѕ Ч лекарственный препарат
  • Ћѕ¬ѕ Ч липопротеины высокой плотности
  • ЋѕЌѕ Ч липопротеины низкой плотности
  • ЋѕќЌѕ Ч липопротеины очень низкой плотности
  • Ћѕ” Ч лечебно-профилактическое учреждение
  • Ћ— Ч лекарственное средство
  • Ћ” Ч лимфатический узел, лимфоузлы
  • Ћ‘  Ч лечебна€ физкультура
  • м.б. Ч может (мог, могут, могли) быть
  • ћ/∆ Ч соотношение мужчин и женщин
  • максƒ Ч максимальна€ доза
  • максЌƒ Ч максимальна€ начальна€ доза
  • макс–ƒ Ч максимальна€ разова€ доза
  • макс—ƒ Ч максимальна€ суточна€ доза
  • ћјЌ  Ч метод амплификации нуклеиновых кислот
  • ћјќ Ч моноаминоксидаза
  • ћ¬ѕ Ч мочевывод€щие пути мг Ч миллиграмм
  • ћƒЅ Ч мышечна€ дистрофи€ Ѕеккера
  • ћƒƒ Ч мышечна€ дистрофи€ ƒюшенна
  • ћƒћј Ч метилендиоксиметамфетамин
  • ME Ч международна€ единица
  • мед. Ч медицинский
  • мес Ч мес€ц
  • ћ∆ Ч молочна€ железа
  • ћ∆ѕ Ч межжелудочкова€ перегородка
  • ћ« Ч министерство здравоохранени€
  • мин Ч минут(а)
  • минƒ Ч минимальна€ доза
  • мин—ƒ Ч минимальна€ суточна€ доза
  • ћ Ѕ Ч мочекаменна€ болезнь
  • ћ Ѕ-10 Ч ћеждународна€ классификаци€ болезней 10-го пересмотра
  • ћ Ѕ-11 Ч ћеждународна€ классификаци€ болезней 11-го пересмотра
  • мк¬ Ч микровольт
  • мкг Ч микрограмм
  • ћ   Ч малый круг кровообращени€
  • мкл Ч микролитр
  • мл Ч миллилитр
  • млн Ч миллион
  • млрд Ч миллиард
  • мм Ч миллиметр
  • мм рт.ст. Ч миллиметр ртутного столба ммоль Ч миллимоль
  • ћЌЌ Ч международное непатентованное наименование
  • ћЌќ Ч международное нормализованное отношение
  • ћќ Ч медицинска€ организаци€
  • ћѕ Ч медицинска€ помощь
  • ћѕ— Ч мочеполова€ система
  • ћ– Ч магнитно-резонансный
  • ћ–-венографи€ Ч ћ–“ вен и синусов головного мозга
  • ћ–“ Ч магнитно-резонансна€ томографи€
  • мс Ч миллисекунда
  • ћ— “ Ч мультиспиральна€ компьютерна€ томографи€
  • ћ—Ё Ч медико-социальна€ экспертиза
  • ћ“ Ч масса тела
  • мтƒЌ  Ч митохондриальна€ дезоксирибонуклеинова€ кислота
  • ћ“– Ч масса тела при рождении
  • ћЁ - миалгический энцефаломиелит
  • н.э. Ч нашей эры
  • Ќј Ч нервна€ анорекси€
  • Ќјƒ Ч никотинамидадениндинуклеотид
  • ЌјƒЌ Ч никотинамидадениндинуклеотид (восстановленный)
  • Ќјƒ‘ Ч никотинамидадениндинуклеотидфосфат
  • Ќј∆Ѕѕ Ч неалкогольна€ жирова€ болезнь печени напр. Ч например
  • ЌЅ Ч нервна€ булими€
  • Ќƒќ Ч негативный детский опыт
  • нед Ч недели
  • нем. Ч немецкий
  • нм Ч нанометр
  • Ќћ»÷ Ч национальный медицинский исследовательский центр
  • Ќћѕ Ч неотложна€ (медицинска€) помощь
  • Ќћ“ Ч низка€ масса тела
  • Ќѕј Ч нормативно-правовой акт
  • Ќѕ¬ Ч нижн€€ пола€ вена
  • Ќѕ¬— Ч нестероидные противовоспалительные средства
  • Ќ— Ч нервна€ система
  • Ќ—“ - нестрессовый тест
  • Ќ–ѕ Ч нормы рациона питани€
  • Ќ—√ Ч нейросонографи€
  • ЌЁ  Ч некротический энтероколит
  • Ќя  Ч неспецифический €звенный колит
  • ќј  Ч общий анализ крови
  • ќјћ Ч общий анализ мочи
  • ќјѕ Ч открытый артериальный проток
  • ќЅѕ Ч органы брюшной полости
  • ќ√Ѕ Ч остра€ горна€ болезнь
  • ќ√ћ Ч отек головного мозга
  • ќƒЌ Ч остра€ дыхательна€ недостаточность
  • ќ∆—— Ч обща€ железосв€зывающа€ способность сыворотки
  • ќ« Ч организаци€ здравоохранени€
  • ок. Ч около
  • ќ – Ч обсессивно-компульсивное расстройство
  • ќ — Ч острый коронарный синдром
  • ќЋЋ Ч острый лимфобластный лейкоз
  • ќћ— Ч об€зательное медицинское страхование
  • ќћ“ Ч органы малого таза
  • ќЌћ  Ч острое нарушение мозгового кровообращени€
  • ќЌћѕ Ч отделение неотложной (медицинской) помощи
  • ќЌћ“ Ч очень низка€ масса тела
  • ќќ« Ч органы (организации/управлени€) здравоохранени€
  • ќќЌ Ч ќрганизаци€ ќбъединенных Ќаций
  • ќѕ∆ Ч ожидаема€ продолжительность жизни
  • ќѕЌ Ч остра€ почечна€ недостаточность
  • ќѕ—— - общее периферическое сосудистое сопротивление
  • ќ–¬» Ч остра€ респираторна€ вирусна€ инфекци€
  • ќ–ƒ— Ч острый респираторный дистресс-синдром
  • ќ–« Ч острое респираторное заболевание
  • ќ–»“ Ч отделение реанимации и интенсивной терапии (ICU)
  • ќ—¬ќ Ч общее содержание воды в организме
  • ќ‘¬ Ч объем форсированного выдоха
  • ќ‘¬1 Ч объем форсированного выдоха за 1-ю секунду
  • ќ÷  Ч объем циркулирующей крови
  • п.з. Ч поле зрени€ (микроскопа)
  • п/к Ч подкожно
  • ѕј¬ Ч психоактивные вещества
  • ѕ¬ Ч протромбиновое врем€
  • ѕ¬  Ч периферический венозный катетер
  • ѕ¬Ћ Ч перивентрикул€рна€ лейкомал€ци€
  • ѕг Ч простагландин
  • ѕ√√ Ч программа государственных гарантий оказани€ гражданам –‘ бесплатной медицинской помощи
  • ѕƒ ¬ Ч положительное давление конца выдоха (PEEP)
  • ѕ∆ Ч правый желудочек
  • ѕ∆∆ Ч поджелудочна€ железа
  • ѕ∆  Ч подкожно-жирова€ клетчатка (гиподерма)
  • ѕ ј Ч почечный канальцевый ацидоз
  • ѕ ћƒ Ч по€сно-конечностна€ мышечна€ дистрофи€
  • ѕЋ—√ Ч п€тниста€ лихорадка —калистых гор
  • ѕћƒ– Ч предменструальное дисфорическое расстройство
  • ѕћ  Ч пролапс митрального клапана
  • ѕћ— Ч предменструальный синдром
  • ѕћ—ѕ Ч первична€ медико-санитарна€ помощь
  • ѕЌ∆  Ч полиненасыщенные жирные кислоты
  • ѕќ–»“Ч педиатрическое отделение реанимации и интенсивной терапии
  • ѕќ“ Ч постуральна€ ортостатическа€ тахикарди€
  • ѕѕ¬ Ч пневмококкова€ полисахаридна€ вакцина
  • ѕѕќј  Ч пр€мые пероральные антикоагул€нты
  • ѕѕ“ Ч площадь поверхности тела
  • ѕ—ј Ч простатоспецифический антиген
  • ѕ—¬ Ч пикова€ скорость выдоха
  • ѕ—¬’ Ч прогрессирующий семейный внутрипеченоч-ный холестаз
  • ѕ“ Ч психотерапи€
  • ѕ“¬ Ч протромбиновое врем€
  • ѕ“√ Ч паратиреоидный гормон
  • ѕ“» Ч протромбиновый индекс
  • ѕ“—– Ч посттравматическое стрессовое расстройство
  • ѕ‘Ё Ч пищевой фолатный эквивалент
  • ѕ÷– Ч полимеразна€ цепна€ реакци€
  • ѕЎ√ Ч пурпура Ўенлейна-√еноха
  • ѕў∆ Ч паращитовидные железы
  • ѕЁ“ Ч позитронно-эмиссионна€ томографи€ р/ Ч раз в ... (с, мин, ч, сут и т.п.)
  • –ј Ч ревматоидный артрит
  • –јј— Ч ренин-ангиотензин-альдостеронова€ система разг. Ч разговорное разл. Ч различное
  • –ј— Ч расстройство аутистического спектра
  • –ƒ— Ч респираторный дистресс-синдром рим. Ч римский
  • –»‘ Ч реакци€ иммунофлюоресценции
  • – » Ч рандомизированные клинические исследовани€
  • – ћѕ Ч рестриктивна€ кардиомиопати€
  • –»√ј Ч реакци€ непр€мой гемагглютинации
  • –Ќ - ретинопати€ недоношенных
  • –Ќ  Ч рибонуклеинова€ кислота
  • –Ќѕ - рекомендуемую норму потреблени€
  • –ќ√  Ч рентгенографи€ (рентгенограмма) органов грудной клетки
  • –ќЋ—Ќ— Ч рекомендации по оценке и лечению при сортировке в неотложных ситуаци€х
  • –ѕ√ј Ч реакци€ пр€мой гемагглютинации
  • р-р Ч раствор
  • р-ритель Ч растворитель
  • ––  Ч рецепторы ретиноевой кислоты
  • PPM Ч расширенные реанимационные меропри€ти€
  • –—¬ Ч респираторно-синцитиальный вирус
  • –—ƒ Ч расстройство стереотипных движений
  • –—  Ч реакци€ св€зывани€ комплемента
  • –—ѕ - расчетна€ средн€€ потребность
  • –“√ј Ч реакци€ торможени€ гемагглютинации
  • –“Ќ√ј Ч реакци€ торможени€ непр€мой гемагглютинации
  • –‘ Ч –оссийска€ ‘едераци€
  • –’– Ч ретиноевые ’-рецепторы
  • –„ј Ч радиочастотна€ абл€ци€
  • –Ё— Ч ретикулоэндотелиальна€ система
  • с Ч секунда
  • св-во Ч свойство
  • —јћ - синдром аспирации мекони€
  • —¬ƒ— Ч синдром внезапной детской смерти
  • —√я Ч синдром гиперстимул€ции €ичников
  • —ƒ Ч сахарный диабет
  • —ƒ-1 Ч сахарный диабет 1-го типа
  • —ƒ-2 Ч сахарный диабет 2-го типа
  • —ƒ¬√ Ч синдром дефицита внимани€ и гиперактивности
  • —≈ Ч субъединица
  • —∆  Ч свободные жирные кислоты
  • —«ƒ - служба защиты детей
  • —«—“ Ч системное(ые) заболевание(€) соединительной ткани
  • —»« Ч средства индивидуальной защиты
  • —»ќ«—Ч селективный ингибитор обратного захвата серотонина
  • —»ќ«—Ќ Ч селективные ингибиторы обратного захвата серотонина и норэпинефрина
  • — ј Ч серповидно-клеточна€ анеми€
  • — ¬ Ч серповидно-клеточна€ болезнь
  • — ¬ Ч системна€ красна€ волчанка
  • — ‘ Ч скорость клубочковой фильтрации
  • —Ћ– Ч сердечно-легочна€ реанимаци€
  • см Ч сантиметр
  • см вод.ст. Ч сантиметр вод€ного столба
  • —ћ∆ Ч спинномозгова€ жидкость
  • —ћ» Ч средства массовой информации
  • —ћќ Ч страхова€ медицинска€ организаци€
  • —ћѕ Ч скора€ медицинска€ помощь
  • —ћЁ Ч судебно-медицинска€ экспертиза
  • —Ќ Ч сердечна€ недостаточность
  • —Ќ—јƒ√ Ч синдром неадекватной секреции јƒ√
  • —ќј— Ч синдром обструктивного апноэ сна (во сне) совр. Ч современный
  • —ќЁ Ч скорость оседани€ эритроцитов
  • —ѕ»ƒ Ч синдром приобретенного иммунодефицита
  • —ѕ я Ч синдром поликистозных €ичников
  • —ѕќЌ Ч синдром полиорганной недостаточности
  • —–¬ Ч —-реактивный белок
  • —–  Ч синдром раздраженного кишечника
  • —р—ƒ Ч средн€€ суточна€ доза
  • ——¬ Ч синдром —терджа-¬ебера
  • ——¬– Ч синдром системной воспалительной реакции
  • ——« Ч сердечно-сосудистые заболевани€
  • ——— Ч сердечно-сосудиста€ система
  • ———” Ч синдром слабости синусового узла
  • —“ Ч —индром “уретта
  • —“√ Ч соматотропный гормон
  • —“– Ч стойкое (хроническое) моторное или вокальное тикозное расстройство
  • сут Ч сутки
  • —’” Ч синдром хронической усталости
  • т.д. Ч так далее
  • т.е. Ч то есть
  • т.к. Ч так как
  • т.о. Ч таким образом
  • т.п. Ч тому подобное
  • “3 Ч трийодтиронин
  • “4 Ч тироксин
  • “јЌ  Ч тест амплификации нуклеиновых кислот
  • “Ѕ— Ч тазобедренный сустав
  • “√¬ Ч тромбоз глубоких вен
  • “√—  Ч трансплантаци€ гемопоэтических стволовых клеток
  • “»ј Ч транзиторна€ ишемическа€ атака
  • “»јЅ Ч тонкоигольна€ аспирационна€ биопси€
  • “ћќ Ч тверда€ мозгова€ оболочка
  • TH Ч торговое наименование лекарственных средств
  • “ѕ√√ Ч территориальна€ программа государственных гарантий оказани€ гражданам –‘ бесплатной медицинской помощи
  • “ѕћ Ч травматическое повреждение мозга
  • ““ Ч температура тела
  • ““√ Ч тиреотропный гормон
  • “‘– Ч трансформирующий фактор роста
  • “÷ј Ч трициклические антидепрессанты
  • тыс. Ч тыс€ча
  • “Ёƒ Чтранзиторна€ эритробластопени€ детского возраста
  • “ЁЋј Ч тромбоэмболи€ легочной артерии
  • “Ёќ Ч тромбоэмболические осложнени€
  • ”«ƒ— Ч ультразвуковое дуплексное сканирование
  • ”«» Ч ультразвуковое исследование
  • устар. Ч устаревшее
  • ”‘ Ч ультрафиолетовый
  • ”‘ќ Ч ультрафиолетовое облучение
  • ‘јѕ Ч фельдшерско-акушерский пункт
  • ‘¬ Ч фракци€ выброса
  • ‘¬ƒ Ч функции внешнего дыхани€
  • ‘∆≈Ћ Ч форсированна€ жизненна€ емкость легких
  • ‘« Ч ‘едеральный закон
  • физиол. Ч физиологический
  • ‘  Ч функциональный класс
  • ‘ — Ч фиброколоноскопи€
  • ‘ ” Ч фенилкетонури€
  • ‘Ќ Ч физическа€ нагрузка
  • ‘»ќ Ч фактор некроза опухоли
  • ‘ќћ— Ч федеральный фонд об€зательного медицинского страховани€
  • ‘ќ— Ч фосфорорганические соединени€
  • ‘ѕ Ч фибрилл€ци€ предсердий
  • фр. Ч французский
  • ‘—√ Ч фолликулостимулирующий гормон
  • ‘Ё√ƒ— Ч фиброэзофагогастродуоденоскопи€
  • ’Ѕѕ Ч хроническа€ болезнь почек
  • ’√„ Ч хорионический гонадотропин человека
  • ’ƒЌ Ч хроническа€ дыхательна€ недостаточность
  • хим. Ч химическа€
  • ’Ќ«Ћ Чхронические неспецифические заболевани€ легких
  • ’ќЅЋ Ч хроническа€ обструктивна€ болезнь легких
  • ’ѕЌ Ч хроническа€ почечна€ недостаточность
  • ’— Ч холестерин
  • ’—Ќ Ч хроническа€ сердечна€ недостаточность
  • XT Ч химиотерапи€
  • ÷¬ƒ Ч центральное венозное давление
  • ÷¬  Ч центральный венозный катетер
  • ÷»  Ч циркулирующие иммунные комплексы
  • ÷ћ¬ Ч цитомегаловирус
  • ÷Ќ— Ч центральна€ нервна€ система
  • ÷ќ√ Ч циклооксигеназа
  • ÷ѕƒ Ч церебральное перфузионное давление
  • ÷—“— Ч церебральный сольтер€ющий синдром ч Ч час
  • „ƒ Ч частота дыхани€
  • „ƒƒ Ч частота дыхательных движений
  • „ ¬ Ч чрескожное коронарное вмешательство
  • „ћЌ Ч черепно-мозговые нервы
  • „ћ“ Ч черепно-мозгова€ травма
  • „Ќ Ч черепные нервы
  • „— Ч чувствительность/специфичность („— 97%/87%)
  • „—— Ч частота сердечных сокращений
  • „——ѕ - частота сердечных сокращений плода
  • „“¬ Ч частичное тромбопластиновое врем€
  • Ў √ Ч шкала комы √лазго
  • Ўќѕ Ч шейный отдел позвоночника
  • ў∆ Ч щитовидна€ железа
  • √÷‘ Ч щелочна€ фосфатаза
  • Ёј– Ч эквивалент активности ретинола
  • Ёƒ“ј Ч этилендиаминтетрауксусна€ кислота (этилендиаминтетраацетат)
  • Ё √ Ч электрокардиографи€
  • Ё ћќ Ч экстракорпоральна€ мембранна€ оксигенаци€
  • Ё ќ Ч экстракорпоральное оплодотворение
  • Ё — Ч электрокардиостимул€тор, элекгрокардиостимул€ци€
  • Ёћ√ Ч электромиографи€
  • Ёћ  Ч электронна€ медицинска€ карта
  • Ёћѕ Ч экстренна€ медицинска€ помощь
  • ЁЌћѕ Ч экстренна€ и неотложна€ медицинска€ помощь
  • ЁЌћ“ Ч экстремально низка€ масса тела
  • Ё““ Ч эндотрахеальна€ трубка
  • Ёхо √ Ч эхокардиографи€
  • ЁЁ√ Ч электроэнцефалографи€
  • ёƒћ Ч ювенильный дерматомиозит
  • ё»ј Ч ювенильный идиопатический артрит
  • яЅ Ч €звенна€ болезнь
  • јј Ч амилоид A (amyloid ј)
  • јј– Ч јмериканска€ академи€ педиатрии (American Academy of Pediatrics)
  • ABC Ч алгоритм неотложной помощи Ђдыхательные пути-дыхание-кровообращениеї (Airways-Breathing-Circulation)
  • ј¬—ј3 Ч белковый член ј“‘-св€зывающей кассеты ј3
  • ј¬—¬11Ч ген ј“‘-св€зывающей кассеты, 11-й член подсемейства ¬ (ATP-binding cassette, sub-family ¬ member 11)
  • ј¬—¬4 Ч ген ј“‘-св€зывающей кассеты, 4-й член подсемейства ¬ (ATP-binding cassette 4 gene)
  • ј¬——2 Ч ген, кодирующий 2-й член подсемейства — ј“‘-св€зывающих кассет (ATP-binding cassette sub-family — member 2)
  • ABCDE Ч алгоритм неотложной помощи Ђдыхательные пути-дыхание-кровообращение-неврологический статус-внешний видї (Airways-Breathing-Circulation-Disability- Exposure)
  • ABCG5/G8 Ч гетеродимер переносчика ј“‘-св€зывающей кассеты ABCG5 и ABCG8 (The heterodimer of ATP-binding cassette transporter ABCG5 and ABCG8)
  • AC Ч до еды (при назначени€х) Ч ante cibum
  • ј—≈– Ч јмериканска€ коллеги€ врачей неотложной помощи (American College of Emergency Physicians)
  • ACOG Ч јмериканска€ коллеги€ акушеров и гинекологов (American College of Obstetricians and Gynecologists)
  • AHA Ч јмериканска€ кардиологическа€ ассоциаци€ (American Heart Association)
  • ALTE Ч очевидное опасное дл€ жизни событие (apparent life-threatening event)
  • APLS Ч курсы расширенных реанимационных меропри€тий в педиатрии, спонсируемые јмериканской академией педиатрии и јмериканской коллегией врачей неотложной помощи (Advanced Pediatric Life Support)
  • ARPKD Ч аутосомно-рецессивный поликистоз почек
  • ASCVD-риск Ч риск развити€ атеросклеротического сердечно-сосудистого заболевани€ (ArterioSclerotic Cardiovascular Disease, ASCVD)
  • AVPU Ч шкала дл€ оценки уровн€ сознани€ (Ђв €сном сознанииї; Ђреакци€ на вербальные раздражителиї; Ђреакци€ на больї; Ђбез сознани€ї) (alert, verbal, pain, unresponsive)
  • BCS Ч митохондриальный шаперон BCS1 (mitochondrial chaperone BCS1)
  • BIN Ч биноминальна€ номенклатура Ђживойї природы
  • BiPAP Ч режим искусственной вентил€ции легких с двум€ уровн€ми положительного давлени€ (bilevel positive airway pressure) = ¬–ј–
  • BNP Ч натрийуретический пептид ¬-типа Ч мозговой (¬ (brain)-type natriuretic peptide)
  • BRUE Ч быстро разрешившиес€ необъ€снимые событи€ (Brief resolved unexplained events)
  • BSEP Ч насос выведени€ солей желчных кислот
  • CADASIL Ч церебральна€ аутосомно-доминантна€ артериопати€ с подкорковыми инфарктами и лейкоэнцефалопатией (cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy)
  • CAPS Ч криопирин-ассоциированный периодический синдром (cryopyrin-associated periodic syndrome)
  • CBIT Ч комплексное поведенческое воздействие при тиках (Comprehensive behavioral intervention for tics)
  • CD Ч кластеры дифференцировки (clusters of differentiation)
  • CDC Ч ÷ентр по контролю и профилактике заболеваний, —Ўј (Center for Disease Control and Prevention)
  • CDG Ч врожденные нарушени€ гликозилировани€ (Congenital Disorder of Glycosylation)
  • CFTR Ч трансмембранный регул€тор муковисцидоза (cystic fibrosis transmembrane regulator)
  • CH Ч гемолитический комплемент (hemolytic complement)
  • CLLS Ч шкала оценки острой горной болезни озера Ћуиз у детей (Childrens Lake Louise Score)
  • CMT Ч Ўарко-ћари-“ута болезнь (Charcot-Marie-Tooth disease)
  • —–ј– Ч посто€нное положительное давление в дыхательных пут€х (Constant Positive Airway Pressure)
  • CYP Ч цитохром общий
  • DAF Ч фактор ускорени€ распада (decay-accelerating factor)
  • DGAT1 Чдиацилглицерин-1-ацилтрансфераза (diacylglycerol acyltransferase 1)
  • DHR Ч дигидрородамин (dihydrorhodamine)
  • DSM Ч ƒиагностическое и статистическое руководство по психическим расстройствам (Diagnostic and Statistical Manual of Mental Disorders)
  • EAST syndrome Ч эпилепси€, атакси€, сенсоневральна€ тугоухость и тубулопати€ (epilepsy, ataxia, sensorineural hearing loss, and tubulopath)
  • EBM Ч доказательна€ медицина (Evidence based medicine)
  • EPCAMЧ молекула адгезии эпителиальных клеток (epithelial cell adhesion molecule)
  • ESC Ч ≈вропейское общество кардиологии (European Society of Cardiology)
  • EXIT Ч лечение вне матки во врем€ родов (Ex utero intrapartum treatment)
  • FAST Ч сфокусированна€ сонографи€ брюшной полости при травме (focused assessment with sonography in trauma)
  • FDA Ч  омитет по контролю за лекарственными веществами и пищевыми добавками, —Ўј (Food and Drug Administration)
  • FFR Ч фракционный резерв кровотока (Fractional Flow Reserve)
  • FGF-23 Ч фактор роста фибробластов-23 (Fibroblast growth factor-23)
  • FIC 1 Чсемейный внутрипеченочный холестаз 1-го типа, болезнь Ѕайлера (familial intrahepatic cholestasis)
  • FiO2 Ч фракци€ кислорода (во вдыхаемом воздухе, газовой смеси)
  • FISH Ч флуоресцентна€ in situ гибридизаци€ (fluorescence in situ hybridization)
  • FLAIR Ч восстановление инверсии с ослаблением жидкости (fluid-attenuated inversion recovery)
  • FMF Ч семейна€ средиземноморска€ лихорадка (Familial Mediterranean fever)
  • GATA Ч gata-св€зывающий белок
  • HADH Ч гидроксилацил- ој-дегидрогеназа (Hydro-xyacyl-Coenzyme A dehydrogenase)
  • HAV Ч вирус гепатита ¬ (hepatitis A virus)
  • Hb Ч гемоглобин
  • HBcAg Ч сердцевинный антиген вируса гепатита ¬
  • HBeAg Ч антиген вируса гепатита ¬
  • HBsAg Ч поверхностный антиген вируса гепатита ¬
  • HBV Ч вирус гепатита ¬ (hepatitis ¬ virus)
  • HCV Ч вирус гепатита — (hepatitis — virus)
  • HDV Ч вирус гепатита D (hepatitis D virus)
  • HFNC Ч назальные канюли высокого потока (heated, high-flow nasal cannula)
  • Hib Ч гемофильна€ палочка типа ¬ (Haemophilus influenzae ¬ type)
  • HLA Ч лейкоцитарные антигены (главного комплекса гистосовместимости) человека (human leukocyte antigens)
  • HR Ч отношение рисков (hazard ratio)
  • HRT Ч терапи€ отмены привычки (Habit reversal therapy)
  • Ht Ч гематокрит
  • HTLV Ч “-лимфотропный вирус человека (human T-lymphotropic virus)
  • Ig Ч иммуноглобулин
  • IgA Ч иммуноглобулин A
  • IgE Ч иммуноглобулин E
  • IgG Ч иммуноглобулин G
  • IgM Ч иммуноглобулин M
  • IL Ч интерлейкин
  • IPEX Ч ’-сцепленный синдром иммунной дисре-гул€ции, полиэндокринопатии и энтеропатии (Immunedysregulation polyendocrinopathy enteropathy, X-linked)
  • IQ Ч коэффициент умственного развити€ (intelligence quotient)
  • JAK Ч €нус-киназа (Janus kinase)
  • LFA Ч антиген, активирующий функцию лейкоцитов (Lymphocyte function-associated antigen)
  • LT Ч лейкотриен
  • MALT Ч лимфоидна€ ткань слизистой оболочки (mucosa-associated lymphoid tissue)
  • MASP Ч ћ—Ћ-ассоциированна€ серинова€ протеаза (MBL-associated serine protease)
  • MBL Ч маннозо-св€зывающий лектин (mannose-
  • binding lectin)
  • MCP Ч мембранный белок-кофактор (membrane cofactor protein)
  • MDR3 Ч белок множественной лекарственной устойчивости 3 (multidrug resistance protein 3)
  • MELAS Ч митохондриальна€ энцефалопати€, лактоацидоз и инсультоподобные эпизоды (mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes)
  • MERRF Ч миоклоническа€ эпилепси€ с рваными красными волокнами (Myoclonic epilepsy with ragged red fibers)
  • Mr Ч кажуща€с€ молекул€рна€ масса
  • MRP Ч белок с множественной лекарственной устойчивостью (multidrug-resistant protein)
  • MRSA Ч метициллинрезистентный золотистый стафилококк
  • MSSA Ч метициллинчувствительный золотистый стафилококк
  • NB! Ч важно, обратить внимание (Nota bene)
  • NICE Ч Ќациональный институт здоровь€ и клинического совершенствовани€ (качества медицинской помощи) ¬еликобритании (National Institute for Health and Clinical Excellence)
  • NK Ч естественные клетки-киллеры (natural killer)
  • NMDA Ч N-метил-D-аспартат (N-methyl-D-aspartate)
  • NMDA Ч N-метил-D-аспартатные рецепторы
  • NNT Ч число больных, которых необходимо пролечить, чтобы достичь какого-то указанного эффекта (Number Need to Treatment)
  • OR Ч отношение шансов (odds ratio)
  • paCO2 Ч парциальное давление углекислого газа в артериальной крови
  • PALS Ч курсы расширенных реанимационных меропри€тий в педиатрии (Pediatric Advanced Life Support)
  • PANDAS Ч аутоиммунное нейропсихиатрическое расстройство в детском возрасте, ассоциированное со стрептококковой инфекцией (Pediatric autoimmune neuropsychiatric disorder associated with streptococcal infection)
  • PANS Ч острый нейропсихиатрический синдром в детском возрасте (Pediatric acute-onset neuropsychiatric syndrome)
  • paO2 Ч парциальное давление кислорода в артериальной крови
  • PAS Ч фуксинсерниста€ кислота, реактив Ўиффа (periodic acid-Shiff)
  • PC Ч после еды (при назначени€х) Ч post cibum р—O2 Ч парциальное давление углекислого газа
  • PCSK-9 Ч пропротеинова€ конвертаза субтилизин-кекси-нового типа 9 (proprotein convertase subtilisin/ kexin type 9)
  • PFAPA Ч периодическа€ лихорадка с афтозным стоматитом, фарингитом и лимфаденитом (Periodic Fevers with Aphthous stomatitis, Pharyngitis and Adenitis)
  • PFIC Ч семейный внутрипеченочный холестаз (familial intrahepatic cholestasis)
  • Pg Ч простагландин
  • pH Ч водородный показатель
  • PIM Ч показатель летального исхода у детей (Pediatric Index of Mortality)
  • piO2 Ч парциальное давление кислорода во вдыхаемом
  • воздухе
  • рO2 Ч парциальное давление кислорода
  • POLG Ч субъединица ƒЌ -полимеразы у
  • PRISA II Ч оценка риска госпитализации у детей II (Pediatric Risk of Admission)
  • PRISM Ч риск летального исхода у детей (Pediatric Risk of Mortality)
  • PRN Ч при (по) необходимости (Pro re nata Ч при возникновении обсто€тельств)
  • PRSS Ч ген сериновой протеазы
  • PS. Ч примечание (Post scriptum)
  • PUVA-терапи€ Ч псорален-ультрафиолет ј-терапи€ (psoralen and ultraviolet ј)
  • Q#H Ч каждые # часов (при назначени€х) Ч quaque ... hora
  • QAM Ч каждое утро (при назначени€х) Ч quaque ante meridiem
  • QPM Ч каждый вечер (при назначени€х) Ч quaque post meridiem
  • RAG Ч ген, активирующий рекомбиназу
  • RePEATЧ пересмотренный инструмент дл€ оценки педиатрической неотложной медицинской помощи (Revised Pediatric Emergency Assessment Tool)
  • RF Ч ревматоидный фактор
  • Rh Ч резус(-фактор)
  • RhЂ-ї Ч резус-отрицательн(ый)
  • RhЂ+ї Ч резус-положительн(ый)
  • ROHHAD Ч быстро развивающеес€ ожирение с дисфункцией гипоталамуса, гиповентил€цией и спонтанной дисрегул€цией (rapid-onset obesity with hypothalamic dysfunction, hypoventilation and autonomic dysregulation)
  • RR Ч относительный риск (relative risk или risk ratio) RW Ч реакци€ ¬ассермана (reaction of Wassermann)
  • SaO2 Ч сатураци€ артериальной крови кислородом SatO2 Ч насыщение крови кислородом
  • ScvO2 Ч насыщение кислородом центральной венозной крови (Central venous oxygen saturation)
  • SD Ч стандартное отклонение (standart deviation) SFTPA Ч ген сурфактантного белка A
  • SFTPB Ч ген сурфактантного белка ¬
  • SFTPC Ч ген сурфактантного белка —
  • SPINK Ч ингибитор сериновой протеазы
  • SpO2 Ч насыщение (сатураци€) гемоглобина кислородом spp. Ч виды (при родовом имени микроорганизмов)
  • Src. Ч источник информации, библиографическа€ ссылка (source)
  • STAT1 Ч сигнальный преобразователь и активатор транскрипции 1 (signal transducer and activator of transcription)
  • TA Ч международна€ анатомическа€ терминологи€ TCR Ч T-клеточный рецептор (T-cell receptor)
  • TLRs Ч “олл-подобные рецепторы (Toll-like receptors) TNF Ч фактор некроза опухоли (tumor necrosis factor)
  • TORCH Ч токсоплазмоз, краснуха, цитомегаловирусна€ инфекци€, герпес и другие инфекции (Toxoplasmosis, Other infections, Rubella, Cytomegalovirus Herpes simplex)
  • TPM Ч мутаци€ тропомиозина (mutation of the tropomyosin)
  • TRAP Ч синдром обратной артериальной перфузии близнецов (twin reversed arterial perfusion)
  • TRAPS Ч периодический синдром, ассоциированный с рецептором фактора некроза опухоли (Tumor Necrosis Factor Receptor-Associated Periodic Syndrome)
  • Щ Ч торгова€ марка
  • URL Ч интернет-ссылка, адрес интернет-ресурса (Uniform Resource Locator)
  • VEGF Ч фактор роста эндотели€ сосудов (Vascular Endothelial Growth Factor)
  • WPW Ч синдром ¬ольфа-ѕаркинсона-”айта (Wolff-Parkinson-White)
  • XLA Ч ’-сцепленна€ агаммаглобулинеми€ (X-linked agammaglobulinemia)
  • aDG-RD Ч дистрофии, св€занные с a-дистрогликанами (alpha dystroglycan-related dystrophies)
  • β-’√„ Ч β-субъединица хорионического гонадотропина человека

¬ ходе подготовки статей по детской гематологии в педиатрии дл€ пользователей сайта ћед”нивер использованы труды следующих авторов:

  1. Christensen RD, Jopling J, Henry E, et al: The erythrocyte indices of neonates, defined using data from over 12,000 patients in a multihospital healthcare system, J Perinatol 28:24Ц28, 2008.
  2. Deutsch VR, Toner A: Megakaryocyte development and platelet production, Br J Haematol 134:453Ц466, 2006.
  3. Jopling J, Henry E, Wiedmeier SE, et al: Reference ranges for hematocrit and blood hemoglobin concentration during the neonatal period: data from a multihospital healthcare system, Pediatrics 123:e333Цe337, 2009.
  4. Julien E, Omar RE, Tavian M: Origin of the hematopoietic system in the human embryo, FEBS Lett 590:3987Ц4001, 2016.
  5. Kaushansky K: Lineage-specific hematopoietic growth factors, N Engl J Med 354: 2034Ц2045, 2006.
  6. Liang R, Ghaffari S: Advances in understanding the mechanisms of erythropoiesis in homeostasis and disease, Br J Haematol 174:661Ц673, 2016.
  7. Liu A, Sola-Visner M: Neonatal and adult megakaryopoiesis, Curr Opin Hematol 18(5):330Ц337, 2011.
  8. Nandakumar SK, Ulrisch JC, Sankaran VG: Advances in understanding erythropoiesis: evolving perspectives, Br J Haematol 173:206Ц218, 2016.
  9. Sola-Visner MC, Christensen RD, Hutson AD, et al: Megakaryocyte size and concentration in the bone marrow of thrombocytopenic and nonthrombocytopenic neonates, Pediatr Res 61:479Ц484, 2007.
  10. Spangrude GJ, Perry SS, Slayton WB: Early stages of hematopoietic differentiation, Ann NY Acad Sci 996:186Ц194, 2003.
  11. Vats A, Bielby RC, Tolley NS, et al: Stem cells, Lancet 366:592Ц602, 2005.
  12. Wang Y, Hayes V, Jarocha D, et al: Comparative analysis of human ex vivoЦgenerated platelets vs megakaryocyte-generated platelets in mice: a cautionary tale, Blood 125(23):3627Ц3636, 2015.
  13. Wiedmeier SE, Henry E, Sola-Visner MC, et al: Platelet reference ranges for neonates, defined using data from over 47,000 patients in a multihospital healthcare system, J Perinatol 29:130Ц136, 2009.
  14. Yoshimoto M, Yoder MC: Developmental biology: birth of the blood cell, Nature 457:801Ц813, 2009.
  15. Noronha SA: Acquired and congenital hemolytic anemia, Pediatr Rev 37(6):235Ц246, 2016.
  16. Powell DJ, Achebe MO: Anemia for the primary care physician, Prim Care 43(4):527Ц542, 2016.
  17. Wang M: Iron deficiency and other types of anemia in infants and children, Am Fam Physician 93(4):270Ц278, 2016.
  18. Crazzolara R, Kropshofer G, Haas OA, et al: Reduced-intensity conditioning and stem cell transplantation in infants with Diamond-Blackfan anemia, Haematologica 102(3):e73Цe75, 2017.
  19. Dietz AC, Mehta PA, Vlachos A, et al: Current knowledge and priorities for future research in late effects after hematopoietic cell transplantation (HCT) for inherited bone marrow failure syndromes (IBMFS): consensus statement from the Second Pediatric Blood and Marrow Transplant Consortium International Conference on Late Effects after Pediatric HCT, Biol Blood Marrow Transplant 23(5):726Ц735, 2017.
  20. Ikeda F, Yoshida K, Toki T, et al: Exome sequencing identified RPS15A as a novel causative gene for Diamond-Blackfan anemia, Haematologica 102(3):e93Цe96, 2017.
  21. Lahoti A, Harris YT, Speiser PW, et al: Endocrine dysfunction in Diamond-Blackfan anemia (DBA): a report from the DBA Registry (DBAR), Pediatr Blood Cancer 63:306Ц312, 2016.
  22. Ludwig LS, Gazda HT, Eng JC, et al: Altered translation of GATA1 in Diamond-Blackfan anemia, Nat Med 20:748Ц753, 2014.
  23. Narla A, Davis NL, Lavasseur C, et al: Erythrocyte adenosine deaminase levels are elevated in Diamond-Blackfan anemia but not in the 5q-syndrome, Am J Hematol 91:E501ЦE502, 2016.
  24. Narla A, Yuan D, Kazerounian S, et al: A novel pathogenic mutation in RPL11 identified in a patient diagnosed with Diamond-Blackfan anemia as a young adult, Blood Cells Mol Dis 61:46Ц47, 2016.
  25. Parrella S, Aspesi A, Quarello P, et al: Loss of GATA-1 full length as a cause of Diamond-Blackfan anemia phenotype, Pediatr Blood Cancer 61:1319Ц1321, 2014.
  26. Vlachos A, Blanc L, Lipton JM: Diamond-Blackfan anemia: a model for the translational approach to understanding human disease, Expert Rev Hematol 7:359Ц372, 2014.
  27. Alter BP: Pearson syndrome in a Diamond-Blackfan anemia cohort, Blood 124:312Ц313, 2014.
  28. Gagne KE, Ghazvinian R, Yuan D, et al: Pearson marrow pancreas syndrome in patients suspected to have Diamond-Blackfan anemia, Blood 124:437Ц440, 2014.
  29. Park J, Ryu H, Jang W, et al: Novel 5.712 kb mitochondrial DNA deletion in a patient with Pearson syndrome: a case report, Mol Med Rep 11:3741Ц3745, 2015.
  30. Sato T, Muroya K, Hanakawa J, et al: Clinical manifestations and enzymatic activities of mitochondrial respiratory chain complexes in Pearson marrow-pancreas syndrome with 3-methylglutaconic aciduria: a case report and literature review, Eur J Pediatr 174:1593Ц1602, 2015.
  31. Shimamura A, Alter BP: Pathophysiology and management of inherited bone marrow failure syndromes, Blood Rev 24:101Ц122, 2010.
  32. Aoki K, Ono Y, Tabata S, et al: Successful treatment of anti-erythropoietin antibodyЦmediated pure red cell aplasia with low-dose prednisolone, Int J Hematol 97:272Ц274, 2013.
  33. Crabol Y, Terrier B, Rozenberg F, et al; Groupe dТexperts de lТAssistance PubliqueHopitaux: Intravenous immunoglobulin therapy for pure red cell aplasia related to human parvovirus B19 infection: a retrospective study of 10 patients and review of the literature, Clin Infect Dis 56:968Ц977, 2013.
  34. Karabulut A, Gok S, Kocyigit A: NonЦimmune hydrops fetalis without anemia due to parvovirus B19, Int J Gynaecol Obstet 124:82, 2014.
  35. MacDougall IC, Casadevall N, Locatelli F, et al: Incidence of erythropoietin antibodyЦmediated pure red cell aplasia: the Prospective Immunogenicity Surveillance Registry (PRIMS), Nephrol Dial Transplant 30:451Ц460, 2015.
  36. Makhlouf MM, Elwakil SG, Ibrahim NS: Molecular and serological assessment of parvovirus B-19 infection in Egyptian children with sickle cell disease, J Microbiol Immunol Infect 2015 Dec 1. pii: S1684-1182(15), 00914-7.
  37. Ruiz Gutierrez L, Albarran F, Moruno H, Cuende E: Parvovirus B19 chronic monoarthritis in a patient with common variable immunodeficiency, Reumatol Clin 11:58Ц59, 2015.
  38. Van den Akker M, Dror Y, Odame I: Transient erythroblastopenia of childhood is an underdiagnosed and self-limiting disease, Acta Paediatr 103:e288Цe294, 2014.
  39. Welcker S, Heckmann M: Non-immune hydrops fetalis due to parvovirus B19 infection in 2 extremely preterm infants: perinatal management and long-term neurodevelopmental outcome, Z Geburtshilfe Neonatol 219:144Ц147, 2015.
  40. Xu LH, Fang JP, Weng WJ, et al: Pure red cell aplasia associated with cytomegalovirus and Epstein-barr virus infection in seven cases of Chinese children, Hematology 18:56Ц59, 2013.
  41. Camaschella C: Iron and hepcidin: a story of recycling and balance, Hematology 2013:1Ц8, 2013.
  42. Fraenkel PG: Understanding anemia of chronic disease, Hematology 2015:14Ц18, 2015.
  43. Gangat N, Wolanskyj AP: Anemia of chronic disease, Semin Hematol 50(3):232Ц238, 2013.
  44. Poggiali E, Migone De Amicis M, Motta I: Anemia of chronic disease: a unique defect of iron recycling for many different chronic diseases, Eur J Intern Med 25:12Ц17, 2014.
  45. Turgeon OТBrien H, Blanchet R, Gagn? D, et al: Using soluble transferrin receptor and taking inflammation into account when defining serum ferritin cutoffs improved the diagnosis of iron deficiency in a group of Canadian preschool inuit children from Nunavik, Anemia 2016:6430214, 2016.
  46. Atkinson MA, Martz K, Warady BA, Neu AM: Risk for anemia in pediatric chronic kidney disease patients: a report of NAPRTCS, Pediatr Nephrol 25:1699Ц1706, 2010.
  47. Atkinson MA, Kim JY, Roy CN, et al: Hepcidin and risk of anemia in CKD: a cross-sectional and longitudinal analysis in the CKiD cohort, Pediatr Nephrol 30:635Ц643, 2015.
  48. Girelli D, Ugolini S, Busti F, et al: Modern iron replacement therapy: clinical and pathophysiological insights, Int J Hematol 107(1):16Ц30, 2018.
  49. Goldstein AL, Morris D, Warady BA: Comparison of the safety and efficacy of 3 iron sucrose iron maintenance regimens in children, adolescents, and young adults with CKD: a randomized controlled trial, Am J Kidney Dis 61:588Ц597, 2013.
  50. Warady BA, Neu AM, Schaefer F: Optimal care of the infant, child, and adolescent on dialysis: 2014 update, Am J Kidney Dis 64:128Ц142, 2014.
  51. Warady BA, Silverstein DM: Management of anemia with erythropoietic-stimulating agents in children with chronic kidney disease, Pediatr Nephrol 29:1493Ц1505, 2014.
  52. Babbs C, Roberts NA, Sanchez-Pulido L, et al: Homozygous mutations in a predicted endonuclease are a novel cause of congenital dyserythropoietic anemia type I, Haematologica 98:1383Ц1387, 2013.
  53. Bianchi P, Schwarz K, Hogel J, et al: Analysis of a cohort of 101 CDAII patients: description of 24 new molecular variants and genotype-phenotype correlations, Br J Haematol 175:696Ц704, 2016.
  54. Gambale A, Iolascon A, Andolfo I, Russo R: Diagnosis and management of congenital dyserythropoietic anemias, Expert Rev Hematol 9:283Ц296, 2016.
  55. Iolascon A, Heimpel H, Wahlin A, Tamary H: Congenital dyserythropoietic anemias: molecular insights and diagnostic approach, Blood 122:2162Ц2166, 2013.
  56. Liljeholm M, Irvine AF, Vikberg AL, et al: Congenital dyserythropoietic anemia type III (CDA III) is caused by a mutation in kinesin family member, KIF23, Blood 121:4791Ц4799, 2013.
  57. Russo R, Gambale A, Langella C, et al: Retrospective cohort study of 205 cases with congenital dyserythropoietic anemia type II: definition of clinical and molecular spectrum and identification of new diagnostic scores, Am J Hematol 89:E169ЦE175, 2014.
  58. Shalev H, Al-Athamen K, Levi I, et al: Morbidity and mortality of adult patients with congenital dyserythropoietic anemia type I, Eur J Haematol 98:13Ц18, 2017.
  59. Anemia of prematurity. In Malcolm W, editor: Beyond the NICU: comprehensive care of the high-risk infant, New York, 2015, McGraw-Hill Education, pp 202Ц210.
  60. Banerjee J, Aladangady N: Biomarkers to decide red blood cell transfusion in newborn infants, Transfusion 54:2574Ц2582, 2014.
  61. Berglund SK, Westrup B, Domell?f M: Iron supplementation until 6 month protects marginally low-birth-weight infants from iron deficiency during their first year of life, JPGN 60(3):390Ц395, 2015.
  62. Katheria AC, Truong G, Cousins L, et al: Umbilical cord milking versus delayed cord clamping in preterm infants, Pediatrics 136:61Ц69, 2015.
  63. Ohls RK, Christensen RD, Kamath-Rayne BD, et al: A randomized, masked, placebocontrolled study of darbepoetin alfa in preterm infants, Pediatrics 132:e119Цe127, 2013.
  64. Ohls RK, Kamath-Rayne BD, Christensen RD, et al: Cognitive outcomes of preterm infants randomized to darbepoetin, erythropoietin, or placebo, Pediatrics 133: 1023Ц1030, 2014.
  65. Whyte RK, Jefferies AL, French Canadian Paediatric Society, Newborn C: Red blood cell transfusion in newborn infants, Paediatr Child Health 19:213Ц222, 2014.
  66. Zhang Y, Jin L, Liu JM, et al: Maternal hemoglobin concentration during gestation and risk of anemia in infancy: secondary analysis of a randomized controlled trial, J Pediatr 175:106Ц110 e2, 2016.
  67. Alpers DH: Absorption and blood/cellular transport of folate and cobalamin: pharmacokinetic and physiological considerations, Biochimie 126:52Ц56, 2016.
  68. DТAco KE, Bearden D, Watkins D, et al: Severe 5,10-methylenetetrahydrofolate reductase deficiency and two MTHFR variants in an adolescent with progressive myoclonic epilepsy, Pediatr Neurol 51:266Ц270, 2014.
  69. Ruiz-Mercado M, Vargas MT, de Soto IP, et al: Methionine synthase reductase deficiency (CblE): a report of two patients and a novel mutation, Hematology 21:193Ц197, 2016.
  70. Zhao R, Aluri S, Goldman ID: The proton-coupled folate transporter (PCFT-SLC46A1) and the syndrome of systemic and cerebral folate deficiency of infancy: hereditary folate malabsorption, Mol Aspects Med 53:57Ц72, 2017.
  71. Bahadir A, Reis PG, Erduran E: Oral vitamin B12 treatment is effective for children with nutritional vitamin B12 deficiency, J Paediatr Child Health 50:721Ц725, 2014.
  72. Ekici F, Tekbas G, Hattapoglu S, et al: Brain MRI and MR spectroscopy findings in children with nutritional vitamin B12 deficiency, Clin Neuroradiol 26:215Ц220, 2016.
  73. Gherasim C, Lofgren M, Banerjee R: Navigating the B(12) road: assimilation, delivery, and disorders of cobalamin, J Biol Chem 288:13186Ц13193, 2013.
  74. Jain R, Singh A, Mittal M, Talukdar B: Vitamin B12 deficiency in children: a treatable cause of neurodevelopmental delay, J Child Neurol 30:641Ц643, 2015.
  75. Krzemien G, Turczyn A, Szmigielska A, Roszkowska-Blaim M: Vitamin B12 deficiency in children (Imerslund-Grasbeck syndrome in two pairs of siblings), Dev Period Med 19:351Ц355, 2015.
  76. Manios Y, Moschonis G, Dekkers R, et al: Vitamin B2, vitamin B12 and total homocysteine status in children and their associations with dietary intake of B-vitamins from different food groups: the Healthy Growth Study, Eur J Nutr 1:321Ц331, 2017.
  77. Montgomery E, Sayer JA, Baines LA, et al: Novel compound heterozygous mutations in AMN cause Imerslund-Grasbeck syndrome in two half-sisters: a case report, BMC Med Genet 16:35, 2015.
  78. Stabler SP: Clinical practice. Vitamin B12 deficiency, N Engl J Med 368:149Ц160, 2013.
  79. Sturm AC, Baack EC, Armstrong MB, et al: Hereditary intrinsic factor deficiency in Chaldeans, JIMD Rep 7:13Ц18, 2013.
  80. Trakadis YJ, Alfares A, Bodamer OA, et al: Update on transcobalamin deficiency: clinical presentation, treatment and outcome, J Inherit Metab Dis 37:461Ц473, 2014.
  81. Nyhan WL, Gangoiti JA: Hereditary orotic aciduria and the excretion of orotidine, Neuropediatrics 47:408Ц409, 2016.
  82. Setoodeh A, Haghighi A, Saleh-Gohari N, et al: Identification of a SLC19A2 nonsense mutation in Persian families with thiamine-responsive megaloblastic anemia, Gene 519:295Ц297, 2013.
  83. Abdullah K, Birken CS, Maguire JL, et al: Re-evaluation of serum ferritin cut-off values for the diagnosis of iron deficiency in children aged 12-36 months, J Pediatr 188:287Ц290, 2017.
  84. American Academy of Pediatrics: Bright Futures: recommendations for preventive pediatric healthcare. https://brightfutures.aap.org/Pages/default.aspx
  85. Andrews NC, Ullrich CK, Fleming MD, et al: Disorders of iron metabolism and sideroblastic anemia. In Orkin SH, Look AT, Nathan DG, editors: Nathan and OskiТs hematology of infancy and childhood, ed 7, Philadelphia, 2009, Saunders.
  86. Ashish KC, Rana N, Malqvist M, et al: Effects of delayed umbilical cord clamping vs early clamping on anemia in infants at 8 and 12 months, JAMA Pediatr 171(3):264Ц270, 2017.
  87. Baker RD, Greer FR, Committee on Nutrition: Clinical report: diagnosis and prevention of iron deficiency and iron deficiency anemia in infants and young children (0-3 years of age), Pediatrics 126:1040Ц1050, 2010.
  88. Berglund SK, Westrup B, Domell?f M: Iron supplementation until 6 months protects marginally low-birth-weight infants from iron deficiency during their first year of life, J Pediatr Gastroenterol Nutr 60(3):390Ц395, 2015.
  89. Berglund SK, Westrup B, H?ggl?f B, et al: Effects of iron supplementation of LBW infants on cognition and behavior at 3 years, Pediatrics 131(1):47Ц55, 2013.
  90. Buchanan GR: Paucity of clinical trials in iron deficiency: lessons learned from study of VLBW infants, Pediatrics 131:e582Цe584, 2013.
  91. Clark KM, Li M, Zhu B, et al: Breastfeeding, mixed, or formula feeding at 9 months of age and the prevalence of iron deficiency and iron deficiency anemia in two cohorts of infants in China, J Pediatr 181:56Ц61, 2017.
  92. Committee Opinion No 684: Delayed umbilical cord clamping after birth, Obstet Gynecol 129(1):e5Цe10, 2017.
  93. Congdon EL, Westerlund A, Algarin C, et al: Iron deficiency in infancy is associated with altered neural correlates of recognition memory at 10 years, J Pediatr 160:1027Ц1033, 2012.
  94. DeLoughery TG: Microcytic anemia, N Engl J Med 371:1324Ц1331, 2014.
  95. Falkingham M, Abdelhamid A, Curtis P, et al: The effects of oral iron supplementation on cognition in older children and adults: a systematic review and meta-analysis, Nutr J 9:4, 2010.
  96. Ferrara M, Capozzi L, Russo R, et al: Reliability of red blood cell indices and formulas to discriminate between beta thalassemia trait and iron deficiency in children, Hematology 15(2):112Ц115, 2010.
  97. Fleming MD, et al: Disorders of iron and copper metabolism, the sideroblastic anemias, and lead toxicity. In Orkin SH, Fisher DE, Ginsberg D, editors: Nathan and OskiТs hematology and oncology of infancy and childhood, ed 8, Philadelphia, 2005, Saunders.
  98. Kiss JE, Brambilla D, Glynn Sa, et al: Oral iron supplementation after blood donation: a randomized clinical trial, JAMA 313(6):575Ц583, 2015.
  99. Khuong-Quang DA, Schwartzentruber J, Westerman M, et al: Iron refractory iron deficiency anemia: presentation with hyperferritinemia and response to oral iron therapy, Pediatrics 131:e620Цe625, 2013.
  100. Litton E, Xiao J, Ho KM: Safety and efficacy of intravenous iron therapy in reducing requirement for allogeneic blood transfusion: systematic review and meta-analysis of randomized clinical trials, BMJ 347:f4822, 2013.
  101. Lopez A, Cacoub P, Macdougall C, Peyrin-Biroulet L: Iron deficiency anaemia, Lancet 387:907Ц916, 2016.
  102. Lukowski AF, Koss M, Burden MJ: Iron deficiency in infancy and neurocognitive functioning at 19 years: evidence of long-term deficits in executive function and recognition memory, Nutr Neurosci 13:54Ц70, 2010.
  103. Maguire JL, Salehi L, Birken CS, et al: Association between total duration of breastfeeding and iron deficiency, Pediatrics 131:e1530Цe1537, 2013.
  104. McDonald SJ, Middleton P, Dowswell T, et al: Effect of timing of umbilical cord clamping of term infants on maternal and neonatal outcomes, Cochrane Database Syst Rev (7):CD004074, 2013.
  105. McDonagh MS, Blazina I, Dana T, et al: Screening and routine supplementation for iron deficiency anemia: a systematic review, Pediatrics 135(4):723Ц733, 2015.
  106. The Medical Letter: Triferic for iron replacement, Med Lett 59(1517):55Ц56, 2017.
  107. The Medical Letter: Ferric carboxymaltose (Injectafer) for iron deficiency anemia, Med Lett 55:99Ц100, 2013.
  108. Miller JL: Iron deficiency anemia: a common and curable disease, Cold Spring Harb Perspect Med 3(7):a011866, 2013.
  109. National Institutes of Health, Office of Dietary Supplements: Dietary supplement fact sheet: iron. https://ods.od.nih.gov/factsheets/Iron-HealthProfessional/.
  110. Pasricha SR, Atkinson SH, Armitage AE, et al: Expression of the iron hormone hepcidin distinguishes different types of anemia in African children, Sci Transl Med 6(255):235re3, 2014.
  111. Powers JM, Buchanan GR: Potential for improved screening, diagnosis and treatment for iron deficiency and iron deficiency anemia in young children, J Pediatr 188:8Ц10, 2017.
  112. Powers JM, Buchanan GR: Diagnosis and management of iron deficiency anemia, Hematol Oncol Clin North Am 28(4):729Ц745, 2014.
  113. Powers JM, Buchanan GR, Adix L, et al: Effect of low-dose ferrous sulfate vs iron polysaccharide complex on hemoglobin concentration in young children with nutritional iron-deficiency anemia, JAMA 317(22):2297Ц2304, 2017.
  114. Powers JM, Shamoun M, McCavit TL, et al: Intravenous ferric carboxymaltose in children with iron deficiency anemia who respond poorly to oral iron, J Pediatr 180:212Ц216, 2016.
  115. Siu AL: Screening for iron deficiency anemia in young children: USPSTF recommendation statement, Pediatrics 136(4):746Ц752, 2015.
  116. Soofii S, Cousens S, Iqbal SP, et al: Effect of provision of daily zinc and iron with several micronutrients on growth and morbidity among young children in Pakistan: a cluster-randomised trial, Lancet 382:29Ц40, 2013.
  117. Thompson J, Biggs BA, Pasricha SR: Effects of daily iron supplementation in 2- to 5-year-old children: systematic review and meta-analysis, Pediatrics 131(4):739Ц753, 2013.
  118. Torsvik IK, Markestad T, Ueland PM, et al: Evaluating iron status and the risk of anemia in young using erythrocyte parameters, Pediatr Res 73(2):214Ц220, 2013.
  119. Zehetner AA, Orr N, Buckmast A, et al: Iron supplementation for the treatment of breath-holding spells in children, Cochrane Database Syst Rev 7:1Ц25, 2010.
  120. Arsenault V, Mailloux C, Bonnefoy A, et al: Iron-refractory iron deficiency anemia may not lead to neurocognitive dysfunction: a case report, Pediatrics 138(1):e1Цe4, 2016.
  121. Avni T, Bieber A, Grossman A, et al: The safety of intravenous iron preparations: systematic review and meta-analysis, Mayo Clin Proc 90(1):12Ц23, 2015.
  122. Camaschella C: New insights into iron deficiency and iron deficiency anemia, Blood Rev 31(4):225Ц233, 2017.
  123. De Falco L, Sanchez M, Silvestri L, et al: Iron refractory iron deficiency anemia, Haematologica 98(6):845Ц853, 2013.
  124. Donker AE, Raymakers RA, Vlasveld LT, et al: Practice guidelines for the diagnosis and management of microcytic anemias due to genetic disorders of iron metabolism or heme synthesis, Blood 123(25):3873Ц3886, quiz 4005, 2014.
  125. Heeney MM, Finberg KE: Iron-refractory iron deficiency anemia (IRIDA), Hematol Oncol Clin North Am 28(4):637Ц652, v, 2014.
  126. Hershko C, Camaschella C: How I treat unexplained refractory iron deficiency anemia, Blood 123(3):326Ц333, 2014.
  127. Sangkhae V, Nemeth E: Regulation of the iron homeostatic hormone hepcidin, Adv Nutr 8(1):126Ц136, 2017.
  128. Wang CY, Meynard D, Lin HY: The role of TMPRSS6/matriptase-2 in iron regulation and anemia, Frontiers Pharmacol 5:114, 2014.
  129. Andrews NC, Ullrich CK, Fleming MD: Disorders of iron metabolism and sideroblastic anemia. In Orkin SH, Look AT, Nathan DG, et al, editors: Nathan and OskiТs hematology of infancy and childhood, ed 7, Philadelphia, 2009, Saunders.
  130. Beaumont-Epinette MP, et al: Hereditary hypotransferrinemia can lead to elevated transferrin saturation and, when associated to HFE or HAMP mutations, to iron overload, Blood Cells Mol Dis 54(2):151Ц154, 2015.
  131. Camaschella C: How I manage patients with atypical microcytic anaemia, Br J Haematol 160:12Ц24, 2012.
  132. Chhetri SK, Mills RJ, Shaunak S, Emsley HC: Copper deficiency, BMJ 348:g3691, 2014.
  133. Dembinski K, Gargasz AE, Dabrow S, et al: Three distinct cases of copper deficiency in hospitalized pediatric patients, Clin Pediatr 51:759Ц762, 2012.
  134. Donker AE, et al: Practice guidelines for the diagnosis and management of microcytic anemias due to genetic disorders of iron metabolism or heme synthesis, Blood 123(25):3873Ц3886, 2014.
  135. Fleming MD: Disorders of iron and copper metabolism, the sideroblastic anemias, and lead toxicity. In Orkin SH, Fisher DE, Ginsberg D, et al, editors: Nathan and OskiТs hematology and oncology of infancy and childhood, ed 8, Philadelphia, 2005, Saunders.
  136. Miyajima H: Aceruloplasminemia, 2003 [updated 2015]. In Pagon RA, Adam MP, Ardinger HH, et al, editors: GeneReviews [internet], Seattle, 1993Ц2017, University of Washington.
  137. Yaish HM, Christensen RD, Lemons RS: Neonatal nonimmune hemolytic anemia, Curr Opin Pediatr 29:12Ц19, 2017.
  138. Andolfo I, Russo R, Gambale A, Iolascon A: New insights on hereditary erythrocyte membrane defects, Haematologica 101:1284Ц1294, 2016.
  139. Bolton-Maggs PHB, Langer JC, Iolascon A, et al: Guidelines for the diagnosis and management of hereditary spherocytosisЧ2011 update, Br J Haematol 156:37Ц49, 2011.
  140. Christensen RD, Yaish HM, Gallagher PG: A pediatricianТs practical guide to diagnosing and treating hereditary spherocytosis in neonates, Pediatrics 135:1107Ц1114, 2015.
  141. Englum BR, Rothman J, Leonard S, et al: Hematologic outcomes after total splenectomy and partial splenectomy for congenital hemolytic anemia, J Pediatr Surg 51:122Ц127, 2016.
  142. Gallagher PG: Abnormalities of the erythrocyte membrane, Pediatr Clin North Am 60:1349Ц1362, 2013.
  143. Iolascon A, Andolfo I, Barcellini W, et al: Recommendations for splenectomy in hereditary hemolytic anemias, Haematologica 102:1304Ц1313, 2017.
  144. Narla J, Mohandas N: Red cell membrane disorders, Int J Lab Hematol 39(S1):47Ц52, 2017.
  145. Pincez T, Guitton C, Gauthier F, et al: Long-term follow-up of subtotal splenectomy for hereditary spherocytosis: a single-center study, Blood 127:1616Ц1618, 2016.
  146. Rice HE: Understanding splenectomy for children with hereditary spherocytosis, Pediatr Blood Cancer 63:1700Ц1701, 2016.
  147. Andolfo I, Russo R, Gambale A, Iolascon A: New insights on hereditary erythrocyte membrane defects, Haematologica 101:1284Ц1294, 2016.
  148. Gallagher PG: Abnormalities of the erythrocyte membrane, Pediatr Clin North Am 60:1349Ц1362, 2013.
  149. Gallagher PG: Hereditary elliptocytosis: spectrin and protein 4.1r, Semin Hematol 41:142Ц164, 2004.
  150. Iolascon A, Andolfo I, Barcellini W, et al: Recommendations for splenectomy in hereditary hemolytic anemias, Haematologica 102:1304Ц1313, 2017.
  151. Narla J, Mohandas N: Red cell membrane disorders, Int J Lab Hematol 39(S1):47Ц52, 2017.
  152. Alper SL: Genetic diseases of PIEZO1 and PIEZO2 dysfunction, Curr Top Membr 79:97Ц134, 2017.
  153. Andolfo I, Russo R, Gambale A, Iolascon A: New insights on hereditary erythrocyte membrane defects, Haematologica 101:1284Ц1294, 2016.
  154. Gallagher PG: Diagnosis and management of rare congenital nonimmune hemolytic disease, Hematology Am Soc Hematol Educ Program 2015:392Ц399, 2015.
  155. Glogowska E, Schneider ER, Maksimova Y, et al: Novel mechanisms of PIEZO1 dysfunction in hereditary xerocytosis, Blood 130(16):1845Ц1856, 2017.
  156. Glogowska E, Lezon-Geyda K, Maksimova Y, et al: Mutations in the gardos channel (KCNN4) are associated with hereditary xerocytosis, Blood 126:1281Ц1284, 2015.
  157. Glogowska E, Gallagher PG: Disorders of erythrocyte volume homeostasis, Int J Lab Hematol 37(S1):85Ц91, 2015.
  158. Iolascon A, Andolfo I, Barcellini W, et al: Recommendations for splenectomy in hereditary hemolytic anemias, Haematologica 102:1304Ц1313, 2017.
  159. Narla J, Mohandas N: Red cell membrane disorders, Int J Lab Hematol 39(S1):47Ц52, 2017.
  160. Adjobo-Hermans MJ, Cluitmans JC, Bosman GJ: Neuroacanthocytosis: observations, theories and perspectives on the origin and significance of acanthocytes, Tremor Other Hyperkinet Mov (N Y) 5:328, 2015.
  161. Brodsky RA: Paroxysmal nocturnal hemoglobinuria, Blood 124:2804Ц2811, 2014.
  162. Denomme GA: Kell and kx blood group systems, Immunohematology 31:14Ц19, 2015.
  163. DeZern AE, Brodsky RA: Paroxysmal nocturnal hemoglobinuria: a complementmediated hemolytic anemia, Hematol Oncol Clin North Am 29:479Ц494, 2015.
  164. Hill A, DeZern AE, Kinoshita T, Brodsky RA: Paroxysmal nocturnal haemoglobinuria, Nat Rev Dis Primers 3:17028, 2017.
  165. Kelly RJ, Hochsmann B, Szer J, et al: Eculizumab in pregnant patients with paroxysmal nocturnal hemoglobinuria, N Engl J Med 373(11):1032Ц1038, 2015.
  166. McNamara LA, Topaz N, Wang X, et al: High risk for invasive meningococcal disease among patients receiving eculizumab (Soliris) despite receipt of meningococcal vaccine, MMWR Morb Mortal Wkly Rep 66(27):734Ц736, 2017.
  167. Mercuri A, Farruggia P, Timeus F, et al: A retrospective study of paroxysmal nocturnal hemoglobinuria in pediatric and adolescent patients, Blood Cells Mol Dis 64:45Ц50, 2017.
  168. Parker CJ: Update on the diagnosis and management of paroxysmal nocturnal hemoglobinuria, Hematology Am Soc Hematol Educ Program 1:208Ц216, 2016.
  169. Risitano AM, Marotta S: Therapeutic complement inhibition in complement-mediated hemolytic anemias: past, present and future, Semin Immunol 28:223Ц240, 2016.
  170. Reiss UM, Schwartz J, Sakamoto KM, et al: Efficacy and safety of eculizumab in children and adolescents with paroxysmal nocturnal hemoglobinuria, Pediatr Blood Cancer 61:1544Ц1550, 2014.
  171. Shen W, Clemente MJ, Hosono N, et al: Deep sequencing reveals stepwise mutation acquisition in paroxysmal nocturnal hemoglobinuria, J Clin Invest 124:4529Ц4538, 2014.
  172. Walker RH: Untangling the thorns: advances in the neuroacanthocytosis syndromes, J Mov Disord 8:41Ц54, 2015.
  173. Abboud MR, Yim E, Musallam KM, et al: Discontinuing prophylactic transfusions increases the risk of silent brain infarction in children with sickle cell disease: data from STOP II, Blood 118(4):894Ц898, 2011.
  174. Ataga KI, Kutlar A, Kanter J, et al: Crizanlizumab for the prevention of pain crises in sickle cell disease, N Engl J Med 376(5):429Ц438, 2017.
  175. Ballas SK, Bauserman RL, McCarthy WF, et al: Hydroxyurea and acute painful crises in sickle cell anemia: effects on hospital length of stay and opioid utilization during hospitalization, outpatient acute care contacts, and at home, J Pain Symptom Manage 40(6):870Ц882, 2010.
  176. Baskin MN, Goh XL, Heeney MM, et al: Bacteremia risk and outpatient management of febrile patients with sickle cell disease, Pediatrics 131(6):1035Ц1041, 2013.
  177. Belmont AP, Nossair F, Brambilla D, et al: Safety of deep sedation in young children with sickle cell disease: a retrospective cohort study, J Pediatr 166:1226Ц1232, 2015.
  178. Berger E, Saunders N, Wang L, et al: Sickle cell disease in children, Arch Pediatr Adolesc Med 163:251255, 2009.
  179. Beyer JE, Simmons LE, Woods GM, et al: A chronology of pain and comfort in children with sickle cell disease, Arch Pediatr Adolesc Med 153(9):913Ц920, 1999.
  180. Bolanos-Meade J, Fuchs EJ, Luznik L, et al: HLA-haploidentical bone marrow transplantation with posttransplant cyclophosphamide expands the donor pool for patients with sickle cell disease, Blood 120(22):4285Ц4291, 2012.
  181. Brandow AM, Zappia KJ, Stucky CL: Sickle cell disease: a natural model of acute and chronic pain, Pain 158:S79ЦS84, 2017.
  182. Brousse V, Elie C, Benkerrou M, et al: Acute splenic sequestration crisis in sickle cell disease: cohort study of 190 paediatric patients, Br J Haematol 156(5):643Ц648, 2012.
  183. Brousseau DC, McCarver DG, Drendel AL, et al: The effect of CYP2d6 polymorphisms on the response to pain treatment for pediatric sickle cell pain crisis, J Pediatr 150(6):623Ц626, 2007.
  184. Brousseau DC, Panepinto JA, Nimmer M, et al: The number of people with sickle-cell disease in the United States: national and state estimates, Am J Hematol 85(1):77Ц78, 2010.
  185. Buchanan ID, Woodward M, Reed GW: Opioid selection during sickle cell pain crisis and its impact on the development of acute chest syndrome, Pediatr Blood Cancer 45(5):716Ц724, 2005.
  186. Burnett MW, Bass JW, Cook BA: Etiology of osteomyelitis complicating sickle cell disease, Pediatrics 101(2):296Ц297, 1998.
  187. Dallas MH, Triplett B, Shook DR, et al: Long-term outcome and evaluation of organ function in pediatric patients undergoing haploidentical and matched related hematopoietic cell transplantation for sickle cell disease, Biol Blood Marrow Transplant 19(5):820Ц830, 2013.
  188. Davis BA, Allard S, Qureshi A, et al: British committee for standards in haematology: guidelines on red cell transfusion in sickle cell disease. Part I. Principles and laboratory aspects, Br J Haematol 176:179Ц191, 2017.
  189. DeBaun MR, Gordon M, McKinstry MJ, et al: Controlled trial of transfusions for silent cerebral infarcts in sickle cell anemia, N Engl J Med 371:699Ц710, 2014.
  190. DeBaun MR, Sarnaik SA, Rodeghier MJ, et al: Associated risk factors for silent cerebral infarcts in sickle cell anemia: low baseline hemoglobin, gender and relative high systolic blood pressure, Blood 119:3684Ц3690, 2012.
  191. DeBaun MR, Struck RC: The intersection between asthma and acute chest syndrome in children with sickle-cell anaemia, Lancet 387:2545Ц2552, 2016.
  192. DeBaun MR, Telfair J: Transition and sickle cell disease, Pediatrics 130:926Ц935, 2012.
  193. Dever DP, Bal RO, Reinisch A, et al: CRISPR/cas9 ?-globin gene targeting in human haematopoietic stem cells, Nature 539(7629):384Ц389, 2016.
  194. Dowling MM, Quinn CT, Plumb P, et al: Acute silent cerebral ischemia and infarction during acute anemia in children with and without sickle cell disease, Blood 120:3891Ц3897, 2012.
  195. Ellison AM, Ota KV, McGowan KL, et al: Pneumococcal bacteremia in a vaccinated pediatric sickle cell disease population, Pediatr Infect Dis J 5:534Ц536, 2012.
  196. Field JJ, Austin PF, An P, et al: Enuresis is a common and persistent problem among children and young adults with sickle cell anemia, Urology 72:81Ц84, 2008.
  197. Frenette PS, Atweh GF: Sickle cell disease: old discoveries, new concepts, and future promise, J Clin Invest 117:850Ц858, 2007. Gillis VL, Senthinathan A, Dzingina M, et al: Management of an acute painful sickle cell episode in hospital: summary of NICE guidance, BMJ 344:e4063, 2012.
  198. Gladwin MT: Cardiovascular complications and risk of death in sickle-cell disease, Lancet 387:2565Ц2572, 2016.
  199. Gluckman E, Cappelli B, Bernaudin F, et al: The pediatric working party of the European society for blood and marrow transplantation, and the center for international blood and marrow transplant research. Sickle cell disease: an international survey of results of HLA-identical sibling hematopoietic stem cell transplantation, Blood 129:1548Ц1556, 2017.
  200. Halasa NB, Shankar SM, Talbot TR, et al: Incidence of invasive pneumococcal disease among individuals with sickle cell disease before and after the introduction of the pneumococcal conjugate vaccine, Clin Infect Dis 44:1428Ц1433, 2007.
  201. Hines PC, McKnight TP, Seto W, et al: Central nervous system events in children with sickle cell disease presenting acutely with headache, J Pediatr 159:472Ц478, 2011.
  202. Hsieh MM, Fithugh CD, Weitzel P, et al: Nonmyeloablative HLA-matched sibling allogeneic hematopoietic stem cell transplantation for severe sickle cell phenotype, JAMA 312:48Ц56, 2014.
  203. Hoppe C: Newborn screening for hemoglobin disorders, Hemoglobin 35(5/6):556Ц564, 2011.
  204. Huang X, Wang Y, Yan W, et al: Production of gene-corrected adult beta globin protein in human erythrocytes differentiated from patient IPSCs after genome editing of the sickle point mutation, Stem Cells 33(5):1470Ц1479, 2015.
  205. Hulbert ML, Scothorn DJ, Panepinto JA, et al: Exchange blood transfusion compared with simple transfusion for first overt stroke is associated with a lower risk of subsequent stroke: a retrospective cohort study of 137 children with sickle cell anemia, J Pediatr 149(5):710Ц712, 2006.
  206. Jain R, Sawhney S, Rizvi SG: Acute bone crises in sickle cell disease: the T1 fat-saturated sequence in differentiation of acute bone infarcts from acute osteomyelitis, Clin Radiol 63:59Ц70, 2008.
  207. Jordan LC, Casella JF, DeBaun MR: Prospects for primary stroke prevention in children with sickle cell anaemia, Br J Haematol 157:14Ц25, 2012.
  208. Kassim AA, Sharma D: Hematopoietic stem cell transplantation for sickle cell disease: the changing landscape, Hematol Oncol Stem Cell Ther 10(4):259Ц266, 2017.
  209. Kato GJ, Steinberg MH, Gladwin MT: Intravascular hemolysis and the pathophysiology of sickle cell disease, J Clin Invest 127:750Ц760, 2017.
  210. King LGC, Bortolusso-Ali S, Cunningham CA, Reid MEG: Impact of a comprehensive sickle cell center on early childhood mortality in a developing country: the jamaican experience, J Pediatr 167:702Ц705, 2015.
  211. Knight-Madden JM, Hambleton JR: Inhaled bronchodilators for acute chest syndrome in people with sickle cell disease, Cochrane Database Syst Rev (7):CD003733, 2012.
  212. Kuhn JP, Slovis TL, Haller JO: CaffeyТs pediatric diagnostic imaging, vol 2, ed 11, St Louis, 2008, Mosby, p 1087.
  213. Kwiatkowski JL, Cohen AR, Garro J, et al: Transfusional iron overload in children with sickle cell anemia on chronic transfusion therapy for secondary stroke prevention, Am J Hematol 87:221Ц223, 2012.
  214. Lehmann GC, Bell TR, Kirkham FJ, et al: Enuresis associated with sleep disordered breathing in children with sickle cell anemia, J Urol 188(4 Suppl):1572Ц1576, 2012.
  215. Lettre G, Bauer DE: Feral haemoglobin in sickle-cell disease: from genetic epidemiology to new therapeutic strategies, Lancet 387:2554Ц2562, 2016.
  216. Madigan C, Malik P: Pathophysiology and therapy for haemoglobinopathies. Part I. Sickle cell disease, Expert Rev Mol Med 8:1Ц23, 2006.
  217. Mahadeo KM, Oyeku S, Taragin B, et al: Increased prevalence of osteonecrosis of the femoral head in children and adolescents with sickle-cell disease, Am J Hematol 86(9):806Ц808, 2011.
  218. Mehari A, Gladwin MT, Tian X, et al: Mortality in adults with sickle cell disease and pulmonary hypertension, JAMA 307:1254Ц1256, 2012.
  219. Meier ER, Miller JL: Sickle cell disease in children, Drugs 72:895Ц906, 2012.
  220. Merritt AL, Haiman C, Henderson SO: Myth: blood transfusion is effective for sickle cell anemia-associated priapism, CJEM 8:119Ц122, 2006.
  221. Miller AC, Gladwin MT: Pulmonary complications of sickle cell disease, Am J Respir Crit Care Med 185:1154Ц1165, 2012.
  222. Miller ST, Kim HY, Weiner D, et al: Inpatient management of sickle cell pain: a Ђsnapshotї of current practice, Am J Hematol 87:333Ц336, 2012.
  223. Naik RP, Derebail VK, Grams ME, et al: Association of sickle cell trait with chronic kidney disease and albuminuria in African Americans, JAMA 312:2115Ц2124, 2014.
  224. National Heart, Lung and Blood Institute: 2014 Expert Panel report on the evidencebased management of sickle cell disease. www.nhlbi.nih.gov/sites/www.nhlbi.nih.gov/files/sickle-cell-disease-report.pdf.
  225. Nicholson GT, Hsu DT, Colan SD, et al: Coronary artery dilation in sickle cell disease, J Pediatr 159:789Ц794, 2011.
  226. Niihara Y, Miller ST, Kanter J, et al: A phase 3 trial of L-glutamine in sickle cell disease, N Engl J Med 379(3):226Ц235, 2018.
  227. Nordness ME, Lynn J, Zacharisen MC, et al: Asthma is a risk factor for acute chest syndrome and cerebral vascular accidents in children with sickle cell disease, Clin Mol Allergy 3:2, 2005.
  228. Norris CF, Smith-Whitley K, McGowan KL: Positive blood cultures in sickle cell disease: time to positivity and clinical outcome, J Pediatr Hematol Oncol 25(5):390Ц395, 2003. Ohene-Frempong K, Weiner SJ, Sleeper LA, et al: Cerebrovascular accidents in sickle cell disease: rates and risk factors, Blood 91:288Ц294, 1998.
  229. Panepinto JA, Bonner M: Health-related quality of life in sickle cell disease: past, present, and future, Pediatr Blood Cancer 59:377Ц385, 2012.
  230. Panepinto JA, Brousseau DC, Hillery CA, et al: Variation in hospitalizations and hospital length of stay in children with vaso-occlusive crises in sickle cell disease, Pediatr Blood Cancer 44:182Ц186, 2005.
  231. Parent F, Bachir D, Inamo J, et al: A hemodynamic study of pulmonary hypertension in sickle cell disease, N Engl J Med 365:44Ц52, 2011.
  232. Piel FB, Patil AP, Howes RE, et al: Global epidemiology of sickle haemoglobin in neonates: a contemporary geostatistical model-based map and population estimates, Lancet 381:142Ц151, 2013.
  233. Piel FB, Steinberg MH, Rees DC: Sickle cell disease, N Engl J Med 376(16):1561Ц1572, 2017.
  234. Platt OS, Thorington BD, Brambilla DJ, et al: Pain in sickle cell disease: rates and risk factors, N Engl J Med 325(1):11Ц16, 1991.
  235. Quillen K, Lane C, Hu E, et al: Prevalence of ceftriaxone-induced red blood cell antibodies in pediatric patients with sickle cell disease and human immunodeficiency virus infection, Pediatr Infect Dis J 27:357Ц358, 2008.
  236. Quinn CT, McKinstry RC, Dowling MM, et al: Acute silent cerebral ischemic events in children with sickle cell anemia, JAMA Neurol 70:58Ц65, 2013.
  237. Quinn CT, Rogers ZR, McCavit TL, et al: Improved survival of children and adolescents with sickle cell disease, Blood 115:3447Ц3452, 2010.
  238. Reagan MM, DeBaun MR, Frei-Jones MJ: Multi-modal intervention for the inpatient management of sickle cell pain significantly decreases the rate of acute chest syndrome, Pediatr Blood Cancer 56:262Ц266, 2011.
  239. Rezende PV, Viana MB, Murao M, et al: Acute splenic sequestration in a cohort of children with sickle cell anemia, J Pediatr (Rio J) 85:163Ц169, 2009.
  240. Ribeil JA, Hacein-Bay-Abina S, Payen E, et al: Gene therapy in a patient with sickle cell disease, N Engl J Med 376(9):848Ц855, 2017.
  241. Ridha A, Khan A, Al-Abayechi S, et al: Acute compartment syndrome secondary to rhabdomyolysis in a sickle cell trait patient, Lancet 384:2172, 2014.
  242. Rogers ZR: Priapism in sickle cell disease, Hematol Oncol Clin North Am 19:917Ц928, viii, 2005.
  243. Scothorn DJ, Price C, Schwartz D, et al: Risk of recurrent stroke in children with sickle cell disease receiving blood transfusion therapy for at least five years after initial stroke, J Pediatr 140:348Ц354, 2002.
  244. Smith WR, Bauserman RL, Ballas SK, et al: Climatic and geographic temporal patterns of pain in the multicenter study of hydroxyurea, Pain 146:91Ц98, 2009.
  245. Smith WR, Penberthy LT, Bovbjerg VE, et al: Daily assessment of pain in adults with sickle cell disease, Ann Intern Med 148:94Ц101, 2008.
  246. Smith-Whitley K, Thompson AA: Indications and complications of transfusions in sickle cell disease, Pediatr Blood Cancer 59:358Ц364, 2012.
  247. Smith-Whitley K, Zhao H, Hodinka RL, et al: Epidemiology of human parvovirus B19 in children with sickle cell disease, Blood 103:422Ц427, 2004.
  248. Switzer JA, Hess DC, Nichols FT, et al: Pathophysiology and treatment of stroke in sickle-cell disease: present and future, Lancet Neurol 5:501Ц512, 2006.
  249. Thornburg CD, Files BA, Luo Z, et al: Impact of hydroxyurea on clinical events in the BABY HUG trial, Blood 120:4304Ц4310, 2012.
  250. Umans H, Haramati N, Flusser G: The diagnostic role of gadolinium enhanced MRI in distinguishing between acute medullary bone infarct and osteomyelitis, Magn Reson Imaging 18:255Ц262, 2000.
  251. Vichinsky EP, Styles LA, Colangelo LH, et al: Acute chest syndrome in sickle cell disease: clinical presentation and course. Cooperative study of sickle cell disease, Blood 89(5):1787Ц1792, 1997.
  252. Wang WC, Ware RE, Miller ST, et al: Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG), Lancet 377:1663Ц1672, 2011.
  253. Ware RE, Davis BR, Schultz WH, et al: Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia: TCD with transfusions changing to hydroxyurea (TWiTCH): a multicenter, open-label, phase 3, non-inferiority trial, Lancet 387:661Ц670, 2016.
  254. Ware RE, de Montalembert M, Tshilolo L, Abboud MR: Sickle cell disease, Lancet 390:311Ц323, 2017.
  255. Ware RE, Helms RW: Stroke with transfusions changing to hydroxyurea (SWiTCH), Blood 119:3925Ц3932, 2012.
  256. Wilimas JA, Flynn PM, Harris S, et al: A randomized study of outpatient treatment with ceftriaxone for selected febrile children with sickle cell disease, N Engl J Med 329:472Ц476, 1993.
  257. Yang YM, Shah AK, Watson M, et al: Comparison of costs to the health sector of comprehensive and episodic health care for sickle cell disease patients, Public Health Rep 110:80Ц86, 1995.
  258. Nelson DA, Deuster PA, Carter IIIR, et al: Sickle cell trait, rhabdomyolysis, and mortality among US army soldiers, N Engl J Med 375(5):425Ц442, 2016.
  259. Ambati SR, Randolph RE, Mennitt K, et al: Longitudinal monitoring of cardiac siderosis using cardiovascular magnetic resonance (CMR) T2* in patients with thalassemia major on various chelation regimens: a 6 year study, Am J Hematol 88:652Ц656, 2013.
  260. Ash-Bernal R, Wise R, Wright SM: Acquired methemoglobinemia: a retrospective series of 138 cases at 2 teaching hospitals, Medicine (Baltimore) 83:265Ц273, 2004.
  261. Baksi AJ, Pennell DJ: Randomized controlled trials of iron chelators for the treatment of cardiac siderosis in thalassemia major, Front Pharmacol 5:217, 2014.
  262. Camaschella C: Treating iron overload, N Engl J Med 368:2325Ц2327, 2013.
  263. Cash C, Arnold DH: Extreme methemoglobinemia after topical benzocaine: recognition by pulse oximetry, J Pediatr 181:319, 2017.
  264. Chui DH, Fucharoen S, Chan V: Hemoglobin H disease: not necessarily a benign disorder, Blood 101:791Ц800, 2003.
  265. Crowley MA, Mollan TL, Abdulmalik OY, et al: A hemoglobin variant associated with neonatal cyanosis and anemia, N Engl J Med 364:1837Ц1842, 2011.
  266. Graff DM, Bosse GM, Sullivan J: Case report of methemoglobinemia in a toddler secondary to topical dapsone exposure, Pediatrics 138(2):e1Цe2, 2016.
  267. Higgs DR, Engel JD, Stamatoyannopoulos G: Thalassemia, Lancet 379:373Ц382, 2012.
  268. Hussein AA, Al-Zaben A, Ghatasheh L, et al: Risk adopted allogeneic hematopoietic stem cell transplantation using a reduced intensity regimen for children with thalassemia major, Pediatr Blood Cancer 60:1345Ц1349, 2013.
  269. Key NS, Derebail VK: Sickle-cell trait: novel clinical significance, Hematology Am Soc Hematol Educ Program 2010:418Ц422, 2010.
  270. Kwiatkowski JL: Current recommendations for chelation for transfusion-dependent thalassemia, Ann N Y Acad Sci 1368:107Ц114, 2016.
  271. Lal A, Goldrich ML, Haines DA, et al: Heterogeneity of hemoglobin H disease in childhood, N Engl J Med 364:710Ц718, 2011.
  272. Martin A, Thompson AA: Thalassemias, Pediatr Clin North Am 60:1383Ц1391, 2013.
  273. Musallam KM, Taher AT, Cappellini MD, et al: Clinical experience with fetal hemoglobin induction therapy in patients with beta-thalassemia, Blood 121:2199Ц2212, quiz 372, 2013.
  274. Patel K, Livni N, Macdonald D: Renal medullary carcinoma, a rare cause of haematuria in sickle cell trait, Br J Haematol 132:1, 2006.
  275. Percy MJ, Lappin TR: Recessive congenital methaemoglobinaemia: cytochrome b(5) reductase deficiency, Br J Haematol 141:298Ц308, 2008.
  276. Peters M, Heijboer H, Smiers F, et al: Diagnosis and management of thalassaemia, BMJ 344:40Ц44, 2012.
  277. Songdej D, Babbs C, Higgs DR: BHFS international consortium: an international registry of survivors with hb BartТs hydrops fetalis syndrome, Blood 9:1251Ц1259, 2017.
  278. Taher AT, Musallam KM, Karimi M, et al: Overview on practices in thalassemia intermedia management aiming for lowering complication rates across a region of endemicity: the OPTIMAL CARE study, Blood 115(10):1886Ц1892, 2010.
  279. Taher AT, Musallam KM, Karimi M, et al: Overview on practices in thalassemia intermedia management aiming for lowering complication rates across a region of endemicity: the OPTIMAL CARE study, Blood 115:1886Ц1892, 2010.
  280. Taher AT, Vichinsky E, Musallam KM, et al: Guidelines for the management of non transfusion dependent thalassaemia (NTDT), Nicosia, Cyprus, 2013, Thalassaemia Internation Federation.
  281. Tsaras G, Owusu-Ansah A, Boateng FO, et al: Complications associated with sickle cell trait: a brief narrative review, Am J Med 122:507Ц512, 2009.
  282. Vichinsky EP: Clinical manifestations of alpha-thalassemia, Cold Spring Harb Perspect Med 3:a011742, 2013.
  283. Vichinsky E, Levine L: Standard of care guidelines for thalassemia, Oakland, CA, 2012, ChildrenТs Hospital.
  284. Vichinsky EP, MacKlin EA, Waye JS, et al: Changes in the epidemiology of thalassemia in north America: a new minority disease, Pediatrics 116:e818Цe825, 2005.
  285. Vichinsky E, Cohen A, Thompson AA, et al: Epidemiologic and clinical characteristics of nontransfusion-dependent thalassemia in the United States, Pediatr Blood Cancer 65(7):e27067, 2018.
  286. Wood JC: Impact of iron assessment by MRI, Hematology Am Soc Hematol Educ Program 2011:443Ц450, 2011.
  287. Aissa K, Kamoun F, Sfaihi L, et al: Hemolytic anemia and progressive neurologic impairment: think about triosephosphate isomerase deficiency, Fetal Pediatr Pathol 33:234Ц238, 2014.
  288. Ayi K, Min-Oo G, Serghides L, et al: Pyruvate kinase deficiency and malaria, N Engl J Med 358:1805Ц1810, 2008.
  289. Beutler E: Glucose-6-phosphate dehydrogenase deficiency, N Engl J Med 331:169Ц173, 1994.
  290. Canu G, De Bonis M, Minucci A, Capoluongo E: Red blood cell PK deficiency: an update of PK-LR gene mutation database, Blood Cells Mol Dis 57:100Ц109, 2016.
  291. Cappellini MD, Fiorelli G: Glucose-6-phosphate dehydrogenase deficiency, Lancet 371:64Ц74, 2008.
  292. Chiarelli LR, Morera SM, Bianchi P, et al: Molecular insights on pathogenic effects of mutations causing phosphoglycerate kinase deficiency, PLoS ONE 7:e32065, 2012.
  293. Christensen RD, Nussenzveig RH, Yaish HM, et al: Causes of hemolysis in neonates with extreme hyperbilirubinemia, J Perinatol 34:616Ц619, 2014.
  294. Climent F, Roset F, Repiso A, et al: Red cell glycolytic enzyme disorders caused by mutations: an update, Cardiovasc Hematol Disord Drug Targets 9:95Ц106, 2009. Coppens S, Koralkova P, Aeby A, et al: Recurrent episodes of myoglobinuria, mental retardation and seizures but no hemolysis in two brothers with phosphoglycerate kinase deficiency, Neuromuscul Disord 26:207Ц210, 2016.
  295. Fujii H, Miwa S: Other erythrocyte enzyme deficiencies associated with nonhaematological symptoms: phosphoglycerate kinase and phosphofructokinase deficiency, Baillieres Best Pract Res Clin Haematol 13:141Ц148, 2000.
  296. Gallagher PG: Diagnosis and management of rare congenital nonimmune hemolytic disease, Hematology Am Soc Hematol Educ Program 2015:392Ц399, 2015.
  297. Gallagher PG, Glader B: Diagnosis of pyruvate kinase deficiency, Pediatr Blood Cancer 63:771Ц772, 2016. Garcia-Gomez M, Calabria A, Garcia-Bravo M, et al: Safe and efficient gene therapy for pyruvate kinase deficiency, Mol Ther 24:1187Ц1198, 2016.
  298. Grace RF, Zanella A, Neufeld EJ, et al: Erythrocyte pyruvate kinase deficiency: 2015 status report, Am J Hematol 90:825Ц830, 2015.
  299. Gunawardena S, Kapilananda GM, Samarakoon D, et al: Prevalence of G6PD deficiency in selected populations from two previously high malaria endemic areas of Sri Lanka, PLoS ONE 12(2):e0171208, 2017.
  300. Howes RE, Battle KE, Satyagraha AW, et al: G6PD deficiency: global distribution, genetic variants and primaquine therapy, Adv Parasitol 81:133Ц201, 2013.
  301. Kaplan M, Hammerman C, Bhutani VK: Parental education and the WHO neonatal G-6-PD screening program: a quarter century later, J Perinatol 35:779Ц784, 2015.
  302. Lee SW, Lai NM, Chaiyakunapruk N, Chong DW: Adverse effects of herbal or dietary supplements in G6PD deficiency: a systematic review, Br J Clin Pharmacol 83:172Ц179, 2017.
  303. Martinov MV, Plotnikov AG, Vitvitsky VM, et al: Deficiencies of glycolytic enzymes as a possible cause of hemolytic anemia, Biochim Biophys Acta 1474:75Ц87, 2000.
  304. McMullin MF: The molecular basis of disorders of red cell enzymes, J Clin Pathol 52:241Ц244, 1999. Riskin A, Gery N, Kugelman A: Glucose-6-phosphate dehydrogenase deficiency and borderline deficiency: association with neonatal hyperbilirubinemia, J Pediatr 161:191Ц196, 2012.
  305. Valentin C, Pissard S, Martin J, et al: Triose phosphate isomerase deficiency in 3 French families: two novel null alleles, a frameshift mutation (TPI Alfortville) and an alteration in the initiation codon (TPI Paris), Blood 96:1130Ц1135, 2000.
  306. Van den Broek L, Heylen E, van den Akker M: Glucose-6-phosphate dehydrogenase deficiency: not exclusively in males, Clin Case Rep 4:1135Ц1137, 2016.
  307. Veneri D, Facchinelli D, Vianello A, et al: Blood smear, a key diagnostic tool in hematology: lessons from two cases of acute hemolysis in previously undiagnosed G6PD deficiency, Am J Hematol 91:1165Ц1166, 2016.
  308. Wong RJ, Stevenson DK: Neonatal hemolysis and risk of bilirubin-induced neurologic dysfunction, Semin Fetal Neonatal Med 20:26Ц30, 2015.
  309. Zanella A, Fermo E, Bianchi P, et al: Red cell pyruvate kinase deficiency: molecular and clinical aspects, Br J Haematol 130:11Ц25, 2005.
  310. Aladjidi N, Fernandes H, Leblanc T, et al: Evans syndrome in children: long-term outcome in a prospective French national observational cohort, Front Pediatr 3:79, 2015.
  311. Aladjidi N, Leverger G, LeBlanc T, et al: New insights into childhood autoimmune hemolytic anemia: a French national observational study of 265 children, Haematologica 96:655Ц663, 2011.
  312. Berentsen S, Ulvestad E, Gjertsen BT, et al: Rituximab for primary cold agglutinin disease: a prospective study of 37 courses of therapy in 27 patients, Blood 103: 2925Ц2928, 2004.
  313. Dierickx D, Kentos A, Delannoy A: The role of rituximab in adults with warm antibody autoimmune hemolytic anemia, Blood 125:3223Ц3229, 2015.
  314. Gehrs BC, Friedberg RC: Autoimmune hemolytic anemia, Am J Hematol 69:258Ц271, 2002. Gormezano NW, Kern D, Pereira OL, et al: Autoimmune hemolytic anemia in systemic lupus erythematosus at diagnosis: differences between pediatric and adult patients, Lupus 26:426Ц430, 2017.
  315. Lechner K, J?ger U: How I treat autoimmune hemolytic anemias in adults, Blood 116:1831Ц1838, 2010.
  316. Miano M: How I manage evans syndrome and AIHA cases in children, Br J Haematol 172:524Ц534, 2016.
  317. Michel M: Classification and therapeutic approaches in autoimmune hemolytic anemia: an update, Expert Rev Hematol 4:607Ц618, 2011.
  318. Price V: Auto-immune lymphoproliferative disorder and other secondary immune thrombocytopenias in childhood, Pediatr Blood Cancer 60(Suppl 1):S12ЦS14, 2013.
  319. Sankaran J, Rodriguez V, Jacob EK, et al: Autoimmune hemolytic anemia in children: mayo clinic experience, J Pediatr Hematol Oncol 38:e120Цe124, 2016.
  320. Sove P, Bourdillon L, Sarrot-Reynauld F, et al: Autoimmune hemolytic anemia and common variable immunodeficiency, Medicine (Baltimore) 87:177Ц184, 2008.
  321. Shanbhag S, Spivak J: Paroxysmal cold hemoglobinuria, Hematol Oncol Clin North Am 29:473Ц478, 2015.
  322. Sparling TG, Andricevic M, Wass H: Remission of cold hemagglutinin disease induced by rituximab therapy, CMAJ 164:1405, 2001.
  323. Teachey DT, Lambert MP: Diagnosis and management of autoimmune cytopenias in childhood, Pediatr Clin North Am 60:1489Ц1511, 2013.
  324. Vagace JM, Bajo R, Gervasini G: Diagnostic and therapeutic challenges of primary autoimmune haemolytic anaemia in children, Arch Dis Child 99:668Ц673, 2014.
  325. Woolley AE, Montgomery MW, Savage WJ, et al: Post-babesiosis warm autoimmune hemolytic anemia, N Engl J Med 376:939Ц946, 2017.
  326. Zecca M, Nobili B, Ramenghi U, et al: Rituximab for the treatment of refractory autoimmune hemolytic anemia in children, Blood 101:3857Ц3861, 2003.
  327. Bose S, Sonny A, Rahman N: A teenager presents with fulminant hepatic failure and acute hemolytic anemia, Chest 147:e100Цe104, 2015.
  328. Fakhouri F, Zuber J, Fr?meaux-Bacchi V, Loirat C: Haemolytic uraemic syndrome, Lancet 390(10095):681Ц696, 2017.
  329. George JN, Nester CM: Syndromes of thrombotic microangiopathy, N Engl J Med 371:654Ц666, 2014.
  330. Hedera P: Update on the clinical management of WilsonТs disease, Appl Clin Genet 10:9Ц19, 2017.
  331. Riedl M, Fakhouri F, Le Quintrec M, et al: Spectrum of complement-mediated thrombotic microangiopathies: pathogenetic insights identifying novel treatment approaches, Semin Thromb Hemost 40:444Ц464, 2014.
  332. Spinale JM, Ruebner RL, Kaplan BS, Copelovitch L: Update on Streptococcus pneumoniae associated hemolytic uremic syndrome, Curr Opin Pediatr 25:203Ц208, 2013.
  333. Trachtman H: HUS and TTP in children, Pediatr Clin North Am 60:1513Ц1526, 2013.
  334. Ye XN, Mao LP, Lou YJ, Tong HY: Hemolytic anemia as first presentation of WilsonТs disease
  335. Barbui T: How to manage children and young adults with myeloproliferative neoplasms, Leukemia 26(7):1452Ц1457, 2012.
  336. Cario H, McMullin MF, Bento C, et al: Erythrocytosis in children and adolescents: classification, characterization, and consensus recommendations for the diagnostic approach, Pediatr Blood Cancer 60:1734Ц1738, 2013.
  337. Cario H, McMullin MF, Pahl HL: Clinical and hematological presentation of children and adolescents with polycythemia vera, Ann Hematol 88(8):713Ц719, 2009.
  338. Cario H, Schwarz K, Herter JM, et al: Clinical and molecular characterization of a prospectively collected cohort of children and adolescents with polycythemia vera, Br J Haematol 142:622Ц626, 2008.
  339. Cazzola M: Introduction to a review series on myeloproliferative neoplasms, Blood 129:667Ц703, 2017.
  340. Geyer H, Scherber R, Kosiorek H, et al: Symptomatic profiles of patients with polycythemia vera: implications of inadequately controlled disease, J Clin Oncol 34(2):151Ц159, 2016.
  341. Hofmann I: Myeloproliferative neoplasms in children, J Hematop 8(3):143Ц157, 2015.
  342. Karow A, Nienhold R, Lundberg P, et al: Mutational profile of childhood myeloproliferative neoplasms, Leukemia 29:2407Ц2409, 2015.
  343. Patnaik MM, Tefferi A: The complete evaluation of erythrocytosis: congenital and acquired, Leukemia 23:834Ц844, 2009.
  344. Pemmaraju N, Mesa R: Evidence for janus kinase (JAK) inhibitors for the prevention of major morbid events in patients with myeloproliferative neoplasms (MPNs), Hematology Am Soc Hematol Educ Program 649Ц651:2015, 2015.
  345. Radia D, Geyer HL: Management of symptoms in polycythemia vera and essential thrombocythemia patients, Hematology Am Soc Hematol Educ Program 2015:340Ц348, 2015.
  346. Spivak JL, Silver RT: The revised world health organization diagnostic criteria for polycythemia vera, essential thrombocytosis, and primary myelofibrosis: an alternative proposal, Blood 112(2):231Ц239, 2008.
  347. Tefferi A: Myeloproliferative neoplasms: a decade of discoveries and treatment advances, Am J Hematol 91(1):50Ц58, 2016.
  348. Teofili L, Foa R, Giona F, et al: Childhood polycythemia vera and essential thrombocytopenia: does their pathogenesis overlap with that of adult patients?, Haematologica 93:169Ц172, 2008.
  349. Teofili L, Giona F, Martini M, et al: Markers of myeloproliferative diseases in childhood polycythemia vera and essential thrombocythemia, J Clin Oncol 25:1048Ц1053, 2007.
  350. Alsafadi TR, Hashmi SM, Youssef HA, et al: Polycythemia in neonatal intensive care unit: risk factors, symptoms, pattern, and management controversy, J Clin Neonatol 3(2):93Ц98, 2014.
  351. Cario H, McMullin MF, Bento C, et al: Erythrocytosis in children and adolescents: classification, characterization, and consensus recommendations for the diagnostic approach, Pediatr Blood Cancer 60(11):1734Ц1738, 2013.
  352. Chauveau A, Luque Paz D, Lecucq L, et al: A new point mutation in EPOR inducing a short deletion in congenital erythrocytosis, Br J Haematol 172(3):475Ц477, 2016.
  353. Giona F, Teofili L, Moleti ML, et al: Thrombocythemia and polycythemia in patients younger than 20 years at diagnosis: clinical and biologic features, treatment, and long-term outcome, Blood 119(10):2219Ц2227, 2012.
  354. Huang LJ, Shen YM, Bulut GB: Advances in understanding the pathogenesis of primary familial and congenital polycythaemia, Br J Haematol 148(6):844Ц852, 2010.
  355. Pagon RA, Adam MP, Ardinger HH, et al: Primary familial and congenital polycythemia. In GeneReviews [Internet], Seattle, 1993Ц2017, University of Washington.
  356. Remon JI, Raghavan A, Maheshwari A: Polycythemia in the newborn, Neoreviews 12:e20, 2011.
  357. Sergueeva AI, Miasnikova GY, Polyakova LA, et al: Complications in children and adolescents with chuvash polycythemia, Blood 125(2):414Ц415, 2015.
  358. Sidhu A, Bhambhani K, Callaghan MU: Novel mutations in the von HippelЦlindau gene associated with congenital polycythemia, Pediatr Blood Cancer 62(6):1113Ц1114, 2015.
  359. Siehr SL, Shi S, Hao S, et al: Exploring the role of polycythemia in patients with cyanosis after palliative congenital heart surgery, Pediatr Crit Care Med 17(3):216Ц222, 2016.
  360. Watchko JF: Common hematologic problems in the newborn nursery, Pediatr Clin North Am 62(2):509Ц524, 2015.
  361. Alter BP, Giri N, Savage SA, et al: Malignancies and survival patterns in the national cancer institute inherited bone marrow failure syndromes cohort study, Br J Haematol 150:179Ц188, 2010.
  362. Ballmaier M, Germeshausen M: Congenital amegakaryocytic thrombocytopenia: clinical presentation, diagnosis, and treatment, Semin Thromb Hemost 37:673Ц681, 2011.
  363. Cada M, Segbefia C, Klaassen R, et al: The impact of category, cytopathology and cytogenetics on development and progression of clonal and malignant myeloid transformation in inherited bone marrow failure syndromes, Haematologica 100:633Ц642, 2015.
  364. Dror Y, Donadieu J, Koglmeier J, et al: Draft consensus guidelines for diagnosis and treatment of Shwachman-diamond syndrome, Ann NY Acad Sci 1242:40Ц55, 2011.
  365. Dufour C: How I manage patients with fanconi anemia, Br J Haematol 178:32Ц47, 2017.
  366. Ghemlas I, Li H, Zlateska B, et al: Improving diagnostic precision, care and syndrome definitions using comprehensive next-generation sequencing for the inherited bone marrow failure syndromes, J Med Genet 52:575Ц584, 2015.
  367. Gueiderikh A, Rosselli F, Neto JBC: A never-ending story: the steadily growing family of the FA and FA-like genes, Genet Mol Biol 40:398Ц407, 2017.
  368. Kottemann MC, Smogorzewska A: Fanconi anaemia and the repair of watson and crick DNA crosslinks, Nature 493:356Ц363, 2013.
  369. Paustian L, Chao MM, Hanenberg H, et al: Androgen therapy in fanconi anemia: a retrospective analysis of 30 years in Germany, Pediatr Hematol Oncol 33:5Ц12, 2016.
  370. Savage SA: Dyskeratosis congenita, synonym: Zinsser-cole-engman syndrome, GeneReviews 2016.
  371. Shimamura A, Alter BP: Pathophysiology and management of inherited bone marrow failure syndromes, Blood Rev 24:101Ц122, 2010.
  372. Tsangaris E, Adams SL, Yoon G, et al: Ataxia and pancytopenia caused by a mutation in TINF2, Hum Genet 124:507Ц513, 2008.
  373. Wegman-Ostrosky T, Savage SA: The genomics of inherited bone marrow failure: from mechanism to the clinic, Br J Haematol 177:526Ц542, 2017.
  374. Weis F, Giudice E, Churcher M, et al: Mechanism of eIF6 release from the nascent 60s ribosomal subunit, Nat Struct Mol Biol 22:914Ц919, 2015.
  375. Babushok D, Bessler M, Olson T: Genetic predisposition to myelodysplastic syndrome and acute myeloid leukemia in children and young adults, Leuk Lymphoma 57:520Ц536, 2016.
  376. Barone A, Lucarelli A, Onofrillo D, et al: Diagnosis and management of acquired aplastic anemia in childhood: guidelines from the marrow failure study group of the pediatric Haemato-oncology Italian association (AIEOP), Blood Cells Mol Dis 55:40Ц47, 2015.
  377. Chung NG, Lee JW, Jang PS, et al: Reduced dose cyclophosphamide, fludarabine, and antithymocyte globulin for sibling and unrelated transplant of children with severe and very severe aplastic anemia, Pediatr Transplant 17:387Ц393, 2013.
  378. Desmond R, Townsley DM, Dumitriu B, et al: Eltrombopag restores trilineage hematopoiesis in refractory severe aplastic anemia that can be sustained on discontinuation of drug, Blood 123:1818Ц1825, 2014.
  379. Dietz AC, Lucchini G, Samarasinghe S, Pulsipher A: Evolving hematopoietic stem cell transplantation strategies in severe aplastic anemia, Curr Opin Pediatr 28:3Ц11, 2016.
  380. Im HJ, Koh KN, Choi ES, et al: Excellent outcome of haploidentical hematopoietic stem cell transplantation in children and adolescents with acquired severe aplastic anemia, Biol Blood Marrow Transplant 19:754Ц759, 2013.
  381. Ngwube A, Hayashi RJ, Murray L, et al: Alemtuzumab based reduced intensity transplantation for pediatric severe aplastic anemia, Pediatr Blood Cancer 62:1270Ц1276, 2015.
  382. Scheinberg P: Prognostic value of telomere attrition in patients with aplastic anemia, Int J Hematol 97:553Ц557, 2013.
  383. Shallis RM, Ahmad R, Zeidan AM: Aplastic anemia: etiology, molecular pathogenesis, and emerging concepts, Eur J Haematol 101:711Ц720, 2018.
  384. Townsley DM, Scheinberg P, Winkler T, et al: Eltrombopag added to standard immunosuppression for aplastic anemia, N Engl J Med 376(16):1540Ц1550, 2017.
  385. Tsoukas MA: Pancytopenia in severe hypothyroidism, Am J Med 127(9):e11Цe12, 2014.
  386. Yoshimi A, Niemeyer CM, Fuhrer MM, et al: Comparison of the efficacy of rabbit and horse antithymocyte globulin for the treatment of severe aplastic anemia in children, Blood 121:860Ц861, 2013.
  387. Yoshizato T, Dumitriu B, Hosokawa K, et al: Somatic mutations and clonal hematopoiesis in aplastic anemia, N Engl J Med 373:35Ц46, 2015.
  388. Bell EF, Strauss RG, Widness JA, et al: Randomized trial of liberal versus restrictive guidelines for red blood cell transfusion in preterm infants, Pediatrics 115:1685Ц1691, 2005.
  389. Bergman FS, Almeida JP, Landoni G, et al: Liberal versus restrictive transfusion strategy in critically ill oncologic patients: the transfusion requirements in critically ill oncologic patients randomized controlled trial, Crit Care Med 45(5):766Ц773, 2017.
  390. Carson JL, Carless PA, H?bert PC: Outcomes using lower vs. higher hemoglobin thresholds for red blood cell transfusion, JAMA 309(1):83Ц84, 2013.
  391. Fergusson DA, H?bert P, Hogan DL, et al: Effect of fresh red blood transfusions on clinical outcomes in premature, very low-birth-weight infants: the ARIPI randomized trial, JAMA 308:1443Ц1451, 2012.
  392. Goel R, Cushing MM, Tobian AR: Pediatric patient blood management programs: not just transfusing little adults, Trans Med Rev 30:235Ц241, 2016.
  393. Goodnough LT, Levy JH, Murphy MF: Concepts of blood transfusions in adults, Lancet 381:1845Ц1852, 2013.
  394. Hobert PC, McDonald BJ, Tinmouth A: Clinical consequences of anemia and red cell transfusion in the critically ill, Crit Care Clin 20:225Ц235, 2004.
  395. Hendrickson JE, Shaz BH, Pereira G, et al: Implementation of a pediatric trauma massive transfusion protocol: a quality improvement initiative, Transfusion 52:1228Ц1236, 2012.
  396. Hwu RS, Spinella PC, Keller MS, et al: The effect of massive transfusion protocol implementation on pediatric trauma care, Transfusion 56:2712Ц2719, 2016.
  397. Josephson CD, Caliendo AM, Easley KA, et al: Blood transfusion and breast milk transmission of cytomegalovirus in very-low-birth-weight infants: a prospective cohort study, JAMA Pediatr 168:1054Ц1062, 2014.
  398. Kirpalani H, Whyte RK, Andersen C, et al: The premature infants in need of transfusion (PINT) study: a randomized, controlled trial of a restrictive (low) versus liberal (high) transfusion threshold for extremely low birth weight infants, J Pediatr 149:301Ц307, 2006.
  399. Lacroix J, H?bert PC, Hutchison JS, et al: Transfusion strategies for patients in pediatric intensive care units, N Engl J Med 356:1609Ц1619, 2007.
  400. Spahn DR, Goodnough LT: Alternatives to blood transfusion, Lancet 381:1855Ц1862, 2013.
  401. Strauss RG: Controversies in the management of the anemia of prematurity using single-donor red blood cell transfusion and/or recombinant human erythropoietin, Transfuse Med Rev 20:34Ц44, 2006.
  402. Strauss RG: Commentary: is it safe to limit allogeneic red blood cell transfusions to neonates? Neonatology 93:217Ц222, 2008.
  403. Strauss RG: How I transfuse red blood cells and platelets to infants, Transfusion 48:209Ц217, 2008.
  404. Strauss RG: Anaemia of prematurity: pathophysiology and treatment, Blood Rev 24:221Ц225, 2010.
  405. Vamvakas EC, Strauss RG: Meta-analysis of controlled clinical trials studying the efficacy of recombinant human erythropoietin in reducing blood transfusions in the anemia of prematurity, Transfusion 41:406, 2001.
  406. Venkatesh V, Khan R, Curley A, et al: The safety and efficacy of red cell transfusions in neonates: a systematic review of randomized controlled trials, Br J Haematol 158:370Ц385, 2012.
  407. Andrew M, Vegh P, Caco C, et al: A randomized controlled trial of platelet transfusions in thrombocytopenic premature infants, J Pediatr 123:285Ц291, 1993.
  408. Baer VL, Lambert DK, Henry E, et al: Severe thrombocytopenia in the NICU, Pediatrics 124:1095Ц1100, 2009.
  409. Christensen RD, Paul DA, Sola-Visner MC, et al: Improving platelet transfusion practices in the neonatal intensive care unit, Transfusion 48:2281Ц2284, 2008.
  410. Curley A, Stanworth SJ, Willoughby K, et al: Randomized trial of platelet transfusion thresholds in neonates, N Engl J Med 2018. doi:10.1056/NEJMoa1807320.
  411. Ferrer-Marin F, Liu ZJ, Gutti R, et al: Neonatal thrombocytopenia and megakaryocytopoiesis, Semin Hematol 47:281Ц288, 2010.
  412. Josephson CD, Granger S, Assmann SF, et al: Bleeding risks are higher in children versus adults given prophylactic platelet transfusions for treatment-induced hypoproliferative thrombocytopenia, Blood 120:748Ц760, 2012.
  413. Josephson CD, Su LL, Christensen RD, et al: Platelet transfusion practices among neonatologists in the United States and Canada: results of a survey, Pediatrics 123:278Ц285, 2009.
  414. Josephson CD, Caliendo AM, Easley KA, et al: Blood transfusion and breast milk transmission of cytomegalovirus in very-low-birth-weight infants: a prospective cohort study, JAMA Pediatr 168:1054Ц1062, 2014.
  415. Sparger KA, Assmann SF, Granger S, et al: Platelet transfusion practices among very-low-birth-weight infants, JAMA Pediatr 170:687Ц694, 2016.
  416. Strauss RG: Platelet transfusion volume reduction: it can be done, but why do it?, Transfusion 53:3029Ц3031, 2013.
  417. Strauss RG: Platelet transfusion in neonates and children. In Sweeney JD, Lozano M, editors: Platelet transfusion therapy, Bethesda, MD, 2013, AABB Press, pp 354Ц369.
  418. Stanworth SJ, Grant-Casey J, Lowe D, et al: The use of fresh-frozen plasma in England: high levels of inappropriate use in adults and children, Transfusion 51:62Ц70, 2011.
  419. Strauss RG: Blood components for infants. In Blajchman M, Cid J, Lonzano M, editors: Blood component preparation: from benchtop to bedside, Bethesda, MD, 2011, AABB Press, pp 211Ц246.
  420. Keir AK, Stanworth SJ: Neonatal plasma transfusion: an evidenced-based review, Transfus Med Rev 30:174Ц182, 2016.
  421. Stanworth SJ, Grant-Casey J, Lowe D, et al: The use of fresh-frozen plasma in England: high levels of inappropriate use in adults and children, Transfusion 51:62Ц70, 2011.
  422. Strauss RG: Blood components for infants. In Blajchman M, Cid J, Lonzano M, editors: Blood component preparation: from benchtop to bedside, Bethesda, MD, 2011, AABB Press, pp 211Ц246.
  423. Venkatesh V, Khan R, Curley A, et al: How we decide when a neonate needs a transfusion, Br J Haematol 160:421Ц433, 2013.
  424. Alter HJ, Kein HG: The hazards of blood transfusion in historical perspective, Blood 112:2617Ц2626, 2008.
  425. Azarow KS: Use of fresh frozen plasma in children, J Pediatr 160(2):185Ц186, 2012.
  426. Blood: a precious resource, Lancet 381:2013, 1789.
  427. Caram-Deelder C, Krueger AL, Evers D, et al: Association of blood transfusion from female donors with and without a history of pregnancy with mortality among males and female transfusion recipients, JAMA 318(15):1471Ц1478, 2017.
  428. Carson JL, Triulzi DJ, Ness PM: Indications for and adverse effects of red-cell transfusion, N Engl J Med 377(13):1261Ц1272, 2017.
  429. Centers for Disease Control and Prevention: Blood donor screening for chagas disease Ч United States, 2006Ц2007, MMWR 56:141Ц143, 2007.
  430. Centers for Disease Control and Prevention: Anaplasma phagocytophilum transmitted through blood transfusion Ч minnesota, 2007, MMWR 57:1145Ц1148, 2008.
  431. Centers for Disease Control and Prevention: West nile virus transmission via organ transplantation and blood transfusion Ч louisiana, 2008, MMWR 58:1263Ц1266, 2009.
  432. Centers for Disease Control and Prevention: Transfusion-related transmission of yellow fever vaccine virus Ч california, 2009, MMWR 59:34Ц36, 2010.
  433. Cooper DJ, McQuilten ZK, Nichol A, et al: Age of red cells for transfusion and outcomes in critically ill adults, N Engl J Med 377(19):1858Ц1867, 2017.
  434. Delaney M, Wendel S, Bercovitz RS: Transfusion reactions: prevention, diagnosis, and treatment, Lancet 388:2825Ц2836, 2016.
  435. Goodnough LT: Blood management: transfusion medicine comes of age, Lancet 381:1791Ц1792, 2013.
  436. Hendrickson JE, Shaz BH, Pereira G, et al: Coagulopathy is prevalent and associated with adverse outcomes in transfused pediatric trauma patients, J Pediatr 160:204Ц209, 2012.
  437. Hladik W, Dollard SC, Mermin J, et al: Transmission of human herpesvirus 8 by blood transfusion, N Engl J Med 355:1331Ц1338, 2006.
  438. Jackups R, Savage W: Gaps in research on adverse events to transfusion in pediatrics, Transfus Med Rev 30:209Ц212, 2016.
  439. Jimenez A, Shaz BH, Bloch EM: Zika virus and the blood supply: what do we know?, Transfus Med Rev 31:1Ц10, 2016.
  440. Josephson CD, Caliendo AM, Easley KA, et al: Blood transfusion and breast milk transmission of cytomegalovirus in very-low-birth-weight infants: a prospective cohort study, JAMA Pediatr 168:1054Ц1062, 2014.
  441. Kekre N, Tokessy M, Mallick R, et al: Is cytomegalovirus testing of blood products still needed for hematopoietic stem cell recipients in the era of universal leukoreduction?, Biol Blood Marrow Trans 19:1719Ц1724, 2013.
  442. Rohde JM, Dimcheff DE, Blumberg N, et al: Health careЦassociated infection after red blood cell transfusion Ч a systematic review and meta-analysis, JAMA 311:1317Ц1326, 2014.
  443. Simonsen KA, Harwell JI, Lainwala S: Clinical presentation and treatment of transfusion-associated babesiosis in premature infants, Pediatrics 128(4):e1019Цe1024, 2011.
  444. Strauss RG: Data-driven blood banking practices for neonatal RBC transfusions, Transfusion 40:1528Ц1540, 2000.
  445. Zieman M, Heuft H-G, Frank K, et al: Window period donations during primary cytomegalovirus infection and risk of transmitted-transmitted infections, Transfusion 53:1088Ц1109, 2013.
  446. Zieman M, Krueger S, Maier AB, et al: High prevalence of cytomegalovirus DNA in plasma samples of blood donors in connection with seroconversion, Transfusion 47:1972Ц1983, editorial, 1955Ц1958, 2007.
  447. Boender J, Kruip MJ, Leebeek FW: A diagnostic approach to mild bleeding disorders, J Thromb Haemost 14:1507Ц1516, 2016.
  448. Branchford B, Di Paola J: Approach to the child with a suspected bleeding disorder. In Orkin SH, Fisher DE, Ginsberg D, et al, editors: Nathan and OskiТs hematology of infancy and childhood, ed 8, Philadelphia, 2015, Saunders Elsevier, pp 951Ц963.
  449. Cantor AB: Hemostasis in the newborn and infant. In Nathan and OskiТs hematology of infancy and childhood, ed 8, Philadelphia, 2015, Saunders Elsevier, pp 128Ц157.
  450. Jaffray J, Young G, Ko RH: The bleeding newborn: a review of presentation, diagnosis, and management, Semin Fetal Neonatal Med 21:44Ц49, 2016.
  451. Levi M, van der Poll T: Coagulation and sepsis, Thromb Res 149:38Ц44, 2017.
  452. Harrison P: The role of PFA-100 testing in the investigation and management of haemostatic defects in children and adults, Br J Haematol 130:3Ц10, 2005.
  453. Lippi G, Franchini M, Montagnana M, et al: Coagulation testing in pediatric patients: the young are not just miniature adults, Semin Thromb Hemost 33:816Ц820, 2007.
  454. Mann KG, Brummel-Ziedens K: Blood coagulation. In Nathan and OskiТs hematology of infancy and childhood, ed 8, Philadelphia, 2015, Saunders Elsevier, pp 964Ц983.
  455. Newman DK, Newman PJ: Platelets and the vessel wall. In Nathan and OskiТs hematology of infancy and childhood, ed 8, Philadelphia, 2015, Saunders Elsevier, pp 951Ц963.
  456. Parmar N, Albisetti M, Berry LR, et al: The fibrinolytic system in newborns and children, Clin Lab 52:115Ц124, 2006. erratum, 52:324, 2006.
  457. Saxonhouse MA, Manco-Johnson MJ: The evaluation and management of neonatal coagulation disorders, Semin Perinatol 33:52Ц65, 2009.
  458. Tomaiulo M, Brass LF, Stalker TJ: Regulation of platelet activation and coagulation and its role in vascular injury and arterial thrombosis, Interv Cardiol Clin 6:1Ц12, 2017.
  459. Versteeg HH, Heemskerk JWM, Levi M, et al: New fundamentals in hemostasis, Physiol Rev 93:327Ц358, 2013.
  460. Aledort LM: The evolution of comprehensive haemophilia care in the United States: perspectives from the frontline, Haemophilia 22:676Ц683, 2016.
  461. Berntorp E, Shapiro AD: Modern haemophilia care, Lancet 379:1447Ц1454, 2012.
  462. Branchford BR, Monahan PE, Di Paola J: New developments in the treatment of pediatric hemophilia and bleeding disorders, Curr Opin Pediatr 25:23Ц30, 2013.
  463. Broderick CR, Herbert RD, Latimer J, et al: Association between physical activity and risk of bleeding in children with hemophilia, JAMA 308:1452Ц1458, 2012.
  464. Coppola A, Tagliaferri A, Di Capua M, et al: Prophylaxis in children with hemophilia: evidence-based achievements, old and new challenges, Semin Thromb Hemost 38(1):79Ц94, 2012.
  465. Di Paola J, Montgomery RR, Gill JC, Flood VH: Hemophilia and von willebrand disease. In Orkin SH, Fisher DE, Ginsberg D, et al, editors: Nathan and OskiТs hematology of infancy and childhood, ed 8, Philadelphia, 2015, Saunders Elsevier, pp 1028Ц1054.
  466. George LA, Fogarty PF: Gene therapy for hemophilia: past, present, and future, Semin Hematol 53:46Ц54, 2016.
  467. Gouw SC, van der Bom JG, Ljung R, et al: Factor VIII products and inhibitor development in severe hemophilia a, N Engl J Med 368:231Ц238, 2013.
  468. Kulkarni R, Soucie JM, Lusher J, et al: Site of initial bleeding episodes, mode of delivery and age of diagnosis in babies with haemophilia diagnosed before the age of 2 years: a report from the centers for disease control and PreventionТs (CDC) universal data collection (UDC) project, Haemophilia 15:1281Ц1290, 2009.
  469. Kumar R, Dunn A, Carcao M: Changing paradigm of hemophilia management: extended half-life concentrates and gene therapy, Semin Thromb Hemost 42:18Ц29, 2016.
  470. Leissinger CA: Advances in the clinical management of inhibitors in hemophilia a and B, Semin Hematol 53:20Ц27, 2016.
  471. Manco-Johnson MJ, Abshire TC, Shapiro AD, et al: Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia, N Engl J Med 357:535Ц544, 2007.
  472. Manco-Johnson MJ: Collision sports and risk of bleeding in children with hemophilia, JAMA 308:1480Ц1481, 2012.
  473. Manco-Johnson MJ, Soucie JM, Gill JC: Prophylaxis usage, bleeding rates and joint outcomes of hemophilia 1999Ц2019: a surveillance project, Blood 129(17):2368Ц2374, 2017.
  474. The Medical Letter: Eloctate for hemophilia a, Med Lett 57(1479):143Ц144, 2015.
  475. Nathwani AC, Reiss UM, Tuddenham EGD, et al: Long-term safety and efficacy of factor IX gene therapy in hemophilia B, N Engl J Med 371(21):1994Ц2004, 2014.
  476. Nathwani AC, Tuddenham EGD, Rangarajan S, et al: Adenovirus-associated virus vector-mediated gene transfer in hemophilia B, N Engl J Med 365:2357Ц2365, 2011.
  477. Oldenburg J, Mahlangu JN, Kim B, et al: Emicizumab prophylaxis in hemophilia a with inhibitors, N Engl J Med 377(9):809Ц818, 2017.
  478. Pasi KJ, Rangarajan S, Georgiev P, et al: Targeting of antithrombin in hemophilia a or B with RNAi therapy, N Engl J Med 377(9):819Ц828, 2017.
  479. Peyvandi F, Ettingshausen CE, Goudemand J, et al: New findings on inhibitor development: from registries to clinical studies, Haemophilia 23(Suppl 1):4Ц13, 2017.
  480. Peyvandi F, Garagiola I, Young G: The past and future of haemophilia: diagnosis, treatments, and its complications, Lancet 388:187Ц197, 2016.
  481. Peyvandi F, Mannucci PM, Garagiola I, et al: A randomized trial of factor VIII and neutralizing antibodies in hemophilia a, N Engl J Med 374(21):2054Ц2064, 2016.
  482. Pipe SW: New therapies for hemophilia, Hematology Am Soc Hematol Educ Program 2016:650Ц656, 2016.
  483. Santagostino E, Martinowitz U, Lissitchkov T, et al: Long-acting recombinant coagulation factor IX albumin fusion protein (rIX-FP) in hemophilia B: results of a phase 3 trial, Blood 127(14):1761Ц1769, 2016.
  484. Shima M, Hanabusa H, Taki M, et al: Factor VIII-mimetic function of humanized bispecific antibody in hemophilia a, N Engl J Med 374(21):2044Ц2052, 2016.
  485. Zimmerman B, Valentino LA: Hemophilia: in review, Pediatr Rev 34:289Ц294, 2011.
  486. Acharya SS: Rare bleeding disorders in children: identification and primary care management, Pediatrics 132(5):882Ц892, 2013.
  487. James P, Salomon O, Mikovic D, Peyvandi F: Rare bleeding disorders: bleeding assessment tools, laboratory aspects and phenotype and therapy of FXI deficiency, Haemophilia 20(Suppl 4):71Ц75, 2014.
  488. Seligsohn U: Factor XI in haemostasis and thrombosis: past, present and future, Thromb Haemost 98:84Ц89, 2007.
  489. Mariani G, Bernardi F: Factor VII deficiency, Semin Thromb Hemost 35:400Ц406, 2009.
  490. Menegatti M, Peyvandi F: Factor X deficiency, Semin Thromb Hemost 35:407Ц415, 2009.
  491. Lancellotti S, De Cristofaro R: Congenital prothrombin deficiency, Semin Thromb Hemost 35:367Ц381, 2009.
  492. Asselta R, Peyvandi F: Factor V deficiency, Semin Thromb Hemost 35:382Ц389, 2009.
  493. Thalji N, Camire RN: Parahemophilia: new insights into factor V deficiency, Semin Thromb Hemost 39:607Ц612, 2013.
  494. Zheng C, Zhang B: Combined deficiency of coagulation factors V and VIII: an update, Semin Thromb Hemost 39:613Ц620, 2013.
  495. Bornikova L, Peyvandi F, Allen G, et al: Fibrinogen replacement therapy for congenital fibrinogen deficiency, J Thromb Haemost 9:1687Ц1704, 2011.
  496. De Moerloose P, Casini A, Neerman-Arbez M: Congenital fibrinogen disorders: an update, Semin Thromb Hemost 39:585Ц595, 2013.
  497. Biswas A, Ivaskevicius V, Thomas A, Oldenburg J: Coagulation factor XIII deficiency: diagnosis, prevalence, and management of inherited and acquired forms, Haemostasiologie 34:160Ц166, 2014.
  498. Dorgalaleh A, Rashidpanah J: Blood coagulation factor XIII and factor XIII deficiency, Blood Rev 30:461Ц475, 2016.
  499. Dreyfus M, Barrois D, Borg JY, et al: Successful long-term replacement therapy with FXIII concentrate (fibrogammin p) for severe congenital factor XIII deficiency: a prospective multicentre study, J Thromb Haemost 9(6):1264Ц1266, 2011.
  500. Bauer KA: Rare coagulation factor abnormalities. In Orkin SH, Nathan DG, Ginsberg D, et al, editors: Nathan and OskiТs hematology of infancy and childhood, ed 7, Philadelphia, 2009, Saunders Elsevier, pp 1525Ц1532.
  501. Carpenter SL, Mathew P: Alpha2-antiplasmin and its deficiency: fibrinolysis out of balance, Haemophilia 14:1250Ц1254, 2008.
  502. Mehta R, Shapiro AD: Plasminogen activator inhibitor type 1 deficiency, Haemophilia 14:1255Ц1260, 2008.
  503. Di Paola J, Montgomery RR, Gill JC, et al: Hemophilia and von willebrand disease. In Orkin SH, Fisher DE, Ginsberg D, editors: Nathan and OskiТs hematology of infancy and childhood, ed 8, Philadelphia, 2015, Saunders Elsevier, pp 1028Ц1054.
  504. Eikenboom J, Federici AB, Dirven RJ, et al: VWF propeptide and ratios between VWF, VWF propeptide, and FVIII in the characterization of type 1 von willebrand disease, Blood 121:2336Ц2339, 2013.
  505. Federici AB: Current and emerging approaches for assessing von willebrand disease in 2016, Int J Lab Hematol 38(Suppl 1):41Ц49, 2016.
  506. Goodeve AC: The genetic basis of von willebrand disease, Blood Rev 24:123Ц135, 2010. James AH, Eikenboom J, Federici AB: State of the art: von willebrand disease, Haemophilia 22(Suppl 5):54Ц59, 2016.
  507. Laffan MA, Lester W, OТDonnell JS, et al: The diagnosis and management of von willebrand disease: a United Kingdom haemophilia centre doctors organization guideline approved by the British committee for standards in haematology, Br J Haematol 167:453Ц465, 2014.
  508. Leebeek FW, Eikenboom JC: Von WillebrandТs disease, N Engl J Med 375:2067Ц2080, 2016.
  509. Mannucci PM, Federici AB, James AH, et al: Von willebrand disease in the 21st century: current approaches and new challenges, Haemophilia 15:1154Ц1158, 2009.
  510. Nichols WL, Hultin MB, James AH, et al: Von willebrand disease (VWD): evidencebased diagnosis and management guidelines, the national heart, Lung and blood institute (NHLBI) expert panel report (USA), Haemophilia 14:171Ц232, 2008.
  511. Andrew M, Paes B, Milner R, et al: Development of the human coagulation system in the full-term infant, Blood 70:165Ц172, 1987.
  512. Bertina RM, Koeleman BP, Koster T, et al: Mutation in blood coagulation factor V associated with resistance to activated protein C, Nature 369:64Ц67, 1994.
  513. Bezemer ID, Bare LA, Doggen CJM, et al: Gene variants associated with deep vein thrombosis, JAMA 299:1306Ц1314, 2008.
  514. Connors JM: Thrombophilia testing and venous thrombosis, N Engl J Med 377(12):1177Ц1186, 2017.
  515. Coppola A, Tufano A, Cerbone AM, et al: Inherited thrombophilia: implications for prevention and treatment of venous thromboembolism, Semin Thromb Hemost 35:683Ц694, 2009.
  516. Hicks LK, Bering H, Carson KR, et al: The ASH choosing wisely campaign: five hematologic tests and treatments to question, Blood 122:3879Ц3883, 2013.
  517. Holzhauer S, Goldenberg NA, Junker R, et al: Inherited thrombophilia in children with venous thromboembolism and the familial risk of thromboembolism: an observational study, Blood 120:1510Ц1515, 2012.
  518. Kreuz W, Stoll M, Junker R, et al: Familial elevated factor VIII in children with symptomatic venous thrombosis and post-thrombotic syndrome: results of a multicenter study, Arterioscler Thromb Vasc Biol 26:1901Ц1906, 2006.
  519. MacCallum P: Diagnosis and management of heritable thrombophilias, BMJ 349:g4387, 2014.
  520. Martinelli I, Bucciarelli P, Artoni A, et al: Anticoagulant treatment with rivaroxaban in severe protein S deficiency, Pediatrics 132(5):e1435Цe1439, 2013.
  521. Middeldorp S, van Hylckama Vlieg A: Does thrombophilia testing help in the clinical management of patients?, Br J Haematol 143:321Ц335, 2008.
  522. Monagle P, Barnes C, Ignjatovic V, et al: Developmental haemostasis: impact for clinical haemostasis laboratories, Thromb Haemost 95:362Ц372, 2006.
  523. Neshat-Vahid S, Pierce R, Hershey D, et al: Association of thrombophilia and catheter associated thrombosis in children: a systematic review and meta-analysis, J Thromb Haemost 14:1749Ц1758, 2016.
  524. Raffini L: Thrombophilia in children: who to test, how, when, and why?, Hematology Am Soc Hematol Educ Program 2008:228Ц235, 2008.
  525. Revel-Vilk SG: Thrombophilia in children with venous thromboembolic disease, Thromb Res 118:59Ц65, 2006.
  526. Segal JB, Brotman DJ, Necochea AJ, et al: Predictive value of factor V Leiden and prothrombin G20210A in adults with venous thromboembolism and in family members of those with a mutation, JAMA 301:2472Ц2484, 2009.
  527. Stevens SM, Woller SC, Bauer KA, et al: Guidance for the evaluation and treatment of hereditary and acquired thrombophilia, J Thromb Thrombolysis 41:154Ц164, 2016.
  528. Thornburg CD, Dixon N, Paulyson-Nunez K, et al: Thrombophilia screening in asymptomatic children, Thromb Res 121:597Ц604, 2008.
  529. Yang JYK, Chan AKC: Pediatric thrombophilia, Pediatr Clin North Am 60:1443Ц1462, 2013.
  530. Young G, Albisetti M, Bonduel M, et al: Impact of inherited thrombophilia on venous thromboembolism in children, Circulation 118:1373Ц1382, 2008.
  531. Aguiar CL, Soybilgic A, Avcin T, Myones BL: Pediatric antiphospholipid syndrome, Curr Rheumatol Rep 17:27, 2015.
  532. Alberts MJ: Genetic of warfarin dosing: one polymorphism at a time, Lancet 382:749Ц751, 2013.
  533. Ansah DA, Patel KN, Montegna L, et al: Tissue plasminogen activator use in children: bleeding complications and thrombus resolution, J Pediatr 171:67Ц72, 2016.
  534. Baskin JL, Pui CH, Reiss U, et al: Management of occlusion and thrombosis associated with long-term indwelling central venous catheters, Lancet 374:159Ц169, 2009.
  535. Branduo LR, Williams S, Kahr WHA, et al: Exercise-induced deep vein thrombosis of the upper extremity, Acta Haematol 115:221Ц229, 2006.
  536. Boller HR, ten Cate-Hoek AJ, Hoes AW, et al: Safely ruling out deep venous thrombosis in primary care, Ann Intern Med 150:229Ц235, 2009.
  537. Castellucci LA, Cameron C, Le Gal G, et al: Clinical and safety outcomes associated with treatment of acute venous thromboembolism: a systematic review and metaanalysis, JAMA 312:1122Ц1134, 2014.
  538. Chang K, Graf E, Davis K, et al: Spectrum of thoracic outlet syndrome presentation in adolescents, Arch Surg 146:1383Ц1387, 2011.
  539. Chopra V, Anand S, Hickner A, et al: Risk of venous thromboembolism associated with peripherally inserted central catheters: a systematic review and meta-analysis, Lancet 382:311Ц324, 2013.
  540. Cohen AT, Harrington RA, Goldhaber SZ, et al: Extended thromboprophylaxis with betrixaban in acutely ill medical patients, N Engl J Med 375(6):534Ц544, 2016.
  541. Di Nisio M, van Es N, B?ller HR: Deep vein thrombosis and pulmonary embolism, Lancet 388:3060Ц3069, 2016.
  542. Eikelboom JW, Weitz JI: Selective factor xa inhibition for thromboprophylaxis, Lancet 372:6Ц8, 2008.
  543. Eikelboom JW, Weitz JI: Idrabiotaparinux treatment for venous thromboembolism, Lancet 379:96Ц98, 2012.
  544. Enden T, Haig Y, Klow NE, et al: Long-term outcome after additional catheter-directed thrombolysis versus standard treatment for acute iliofemoral deep vein thrombosis (the CaVent study): a randomized controlled trial, Lancet 379:31Ц38, 2012.
  545. Fischer HD, Juurlink DN, Mamdani MM, et al: Hemorrhage during warfarin therapy associated with cotrimoxazole and other urinary tract anti-infective agents, Arch Intern Med 170:617Ц621, 2010.
  546. Gaballah M, Shi J, Kukreja K, et al: Endovascular thrombolysis in the management of iliofemoral thrombosis in children: a multi-institutional experience, J Vasc Interv Radiol 27:524Ц530, 2016.
  547. Gage BF, Bass AR, Lin H, et al: Effect of genotype-guided warfarin dosing on clinical events and anticoagulation control among patients undergoing hip or knee arthroplasty, JAMA 318:1115Ц1124, 2017.
  548. Giannakopoulos B, Krilis SA: The pathogenesis of the antiphospholipid syndrome, N Engl J Med 368:1033Ц1042, 2013.
  549. Giordano P, Tesse R, Lassandro G, et al: Clinical and laboratory characteristics of children positive for antiphospholipid antibodies, Blood Transfus 10:296Ц301, 2012.
  550. Goldenberg NA: Long-term outcomes of venous thrombosis in children, Curr Opin Hematol 12:370Ц376, 2005.
  551. Goldenberg NA, Durham JD, Knapp-Clevenger R, et al: A thrombolytic regimen for high-risk deep venous thrombosis may substantially reduce the risk of postthrombotic syndrome in children, Blood 110:45Ц53, 2007.
  552. Goldenberg NA, Pounder E, Knapp-Clevenger R, et al: Validation of upper extremity post-thrombotic syndrome outcome measurement in children, J Pediatr 157:852Ц855, 2010.
  553. Gupta A, Johnson DH, Nagalla S: Antiphospholipid antibodies, JAMA 318:959Ц960, 2017.
  554. The Hokusai-VTE Investigators: Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism, N Engl J Med 369:1406Ц1414, 2013.
  555. Hunt BJ: Pediatric antiphospholipid antibodies and antiphospholipid syndrome, Semin Thromb Hemost 34:274Ц281, 2008.
  556. Kearon C, Akl EA, Ornelas J, et al: Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report, Chest 149:315Ц352, 2016.
  557. Kuhle S, Eulmesekian P, Massicotte P, et al: A clinically significant incidence of bleeding in critically ill children receiving therapeutic doses of unfractionated heparin: a prospective cohort study, Haematologica 92:244Ц247, 2007.
  558. Kyrle PA: Vitamin K antagonists: self-determination by self-monitoring?, Lancet 379:292Ц293, 2012.
  559. Landenfeld CS: Noninvasive diagnosis of deep vein thrombosis, JAMA 300:1696Ц1697, 2008.
  560. Le Gal G, Kercret G, Yahmed KB, et al: Diagnostic value of single compete compression ultrasonography in pregnant and postpartum women with suspected deep vein thrombosis: prospective study, BMJ 344:16, 2012.
  561. Lee A, Crowther M: Practical issues with vitamin K antagonists: elevated INRs, low time-in-therapeutic range, and warfarin failure, J Thromb Thrombolysis 31:249Ц258, 2011.
  562. Lyle CA, Sidonio RF, Goldenberg NA: New developments in pediatric venous thromboembolism and anticoagulation, including the target-specific oral anticoagulants, Curr Opin Pediatr 27:18Ц25, 2015.
  563. Manco-Johnson MJ: How I treat venous thrombosis in children, Blood 107:21Ц29, 2007.
  564. Manco-Johnson MJ, Wang M, Goldenberg NA, et al: Treatment, survival, and thromboembolic outcomes of thrombotic storm in children, J Pediatr 161:682Ц688, 2012.
  565. The Medical Letter: Antithrombotic drugs, Med Lett 56:103Ц108, 2014.
  566. The Medical Letter: Dabigatran etexilate (Pradaxa) Ч a new oral anticoagulant, Med Lett Drugs Ther 52(1351):89Ц90, 2010.
  567. The Medical Letter: Prothrombin complex concentrates to reverse warfarin-related bleeding, Med Lett Drugs Ther 53:78Ц80, 2011.
  568. The Medical Letter: Rethinking warfarin for atrial fibrillation, Med Lett Drugs Ther 55:77Ц78, 2013.
  569. The Medical Letter: Apixaban (Eliquis) Ч a new oral anticoagulant for atrial fibrillation, Med Lett Drugs Ther 55:9Ц10, 2013.
  570. The Medical Letter: Kcentra: a 4-factor prothrombin complex concentrate for reversal of warfarin anticoagulation, Med Lett Drugs Ther 55:53, 2013.
  571. The Medical Letter: Edoxaban (Savaysa): the fourth new oral anticoagulant, Med Lett 57:43Ц46, 2015.
  572. Miyawaki Y, Suzuki A, Fujita J, et al: Thrombosis from a prothrombin mutation conveying antithrombin resistance, N Engl J Med 366:2390Ц2396, 2012.
  573. Monagle P, Chan A, Goldenberg N, et al: Antithrombotic therapy in neonates and children: American college of chest physicians Evidence-based clinical practice guidelines, Chest 141:e737SЦ801S, 2012.
  574. Pollack CV Jr, Reilly PA, van Ryn J, et al: Idarucizumab for dabigatran reversal: full cohort analysis, N Engl J Med 377:431Ц441, 2017
  575. Raffini L, Huang YS, Witmer C, et al: Dramatic increase in venous thromboembolism in childrenТs hospitals in the United States from 2001 to 2007, Pediatrics 124:1001Ц1008, 2009.
  576. Richard AA, Kim S, Moffett BS, et al: Comparison of anti-xa levels in obese and non-obese pediatric patients receiving treatment doses of enoxaparin, J Pediatr 162:293Ц296, 2013.
  577. Riley TR, Gauthier-Lewis ML, Sanchez CK, Douglas JS: Role of agents for reversing the effects of target-specific oral anticoagulants, Am J Health Syst Pharm 74:54Ц61, 2017.
  578. Rondina MT, Pendleton RC, Wheeler M, et al: The treatment of venous thromboembolism in special populations, Thromb Res 119:391Ц402, 2007.
  579. Roy PM: Diagnosis of venous thromboembolism, BMJ 339:412Ц413, 2009.
  580. Ruiz-Irastorza G, Crowther M, Branch W, et al: Antiphospholipid syndrome, Lancet 376:1498Ц1506, 2010.
  581. Saracco P, Bagna R, Gentilomo C, et al: Clinical data of neonatal systemic thrombosis, J Pediatr 171:60Ц66, 2016.
  582. Schulman S, Kearon C, Kakkar AJ, et al: Dabigatran versus warfarin in the treatment of acute venous thromboembolism, N Engl J Med 361:2342Ц2352, 2009.
  583. Schulman S, Kearon C, Kakkar AK, et al: Extended use of dabigatran, warfarin, or placebo in venous thromboembolism, N Engl J Med 368:709Ц718, 2013.
  584. Siegel DM, Curnutte JT, Connolly SJ, et al: Andexanet alfa for the reversal of factor xa inhibitor activity, N Engl J Med 373:2413Ц2424, 2015.
  585. Stegeman BH, de Bastos M, Rosendaal FR, et al: Different combined oral contraceptives and the risk of venous thrombosis: systematic review and network meta-analysis, BMJ 347:11, 2013.
  586. Tremor CC III, Chung RJ, Michelson AD, et al: Hormonal contraception and thrombotic risk: a multidisciplinary approach, Pediatrics 127:347Ц357, 2011.
  587. Tuckuviene R, Christensen AL, Helgestad J, et al: Pediatric venous and arterial noncerebral thromboembolism in Denmark: a nationwide population-based study, J Pediatr 159:663Ц669, 2011.
  588. Van Es N, Coppens M, Schulman S, et al: Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials, Blood 124:1968Ц1975, 2014.
  589. Verheugt FWA, Granger CB: Oral anticoagulants for stroke prevention in atrial fibrillation: current status, special situations, and unmet needs, Lancet 386:303Ц310, 2015.
  590. Wells PS, Forgie MA, Rodger MA: Treatment of venous thromboembolism, JAMA 311:717Ц726, 2014.
  591. Young G, Albisetti M, Bonduel M, et al: Impact of inherited thrombophilia on venous thromboembolism in children: a systematic review and meta-analysis of observational studies, Circulation 118:1373Ц1382, 2008.
  592. Burke CW: Vitamin K deficiency bleeding: overview and considerations, J Pediatr Health Care 27:215Ц221, 2013.
  593. Pipe SW, Goldenberg NA, et al: Acquired disorders of hemostasis. In Orkin SH, Fisher DE, Ginsberg D, editors: Nathan and OskiТs hematology of infancy and childhood, ed 8, Philadelphia, 2015, Saunders Elsevier, pp 1103Ц1124.
  594. Yates SR, Sarode R: New strategies for effective treatment of vitamin K antagonistЦ associated bleeding, J Thromb Haemost 13(Suppl 1):S180ЦS186, 2015.
  595. Magnusson M, Ignjatovic V, Hardikar W, Monagle P: A conceptual and practical approach to haemostasis in paediatric liver disease, Arch Dis Child 101:854Ц859, 2016.
  596. Pandit TN, Sarode R: Blood component support in acquired coagulopathic conditions: is there a method to the madness?, Am J Hematol 87(Suppl 1):S56ЦS62, 2012.
  597. Pipe SW, Goldenberg NA: Acquired disorders of hemostasis. In Orkin SH, Fisher DE, Ginsberg D, et al, editors: Nathan and OskiТs hematology of infancy and childhood, ed 8, Philadelphia, 2015, Saunders Elsevier, pp 1103Ц1124.
  598. Tripodi A, Mannucci PM: The coagulopathy of chronic liver disease, N Engl J Med 365(2):147Ц156, 2011.
  599. Wicklund BM: Bleeding and clotting disorders in pediatric liver disease, Hematology Am Soc Hematol Educ Program 2011:170Ц177, 2011.
  600. Collins WP, Chalmers E, Hart D, et al: Diagnosis and management of acquired coagulation inhibitors: a guideline from UKHCDO, Br J Haematol 162:758Ц773, 2013.
  601. Hunt BJ: Pediatric antiphospholipid antibodies and antiphospholipid syndrome, Semin Thromb Hemost 34:274Ц281, 2008.
  602. Janbain M, Leissinger CA, Kruse-Jarres R: Acquired hemophilia a: emerging treatment options, J Blood Med 8:143Ц150, 2015.
  603. Kessler CM, Kn?bl P: Acquired hemophilia: an overview for clinical practice, Eur J Haematol 95(Suppl 81):36Ц44, 2015.
  604. Mazodier K, Arnaud L, Mathian A, et al: Lupus anticoagulant-hypoprothrombinemia syndrome: report of 8 cases and review of the literature, Medicine (Baltimore) 91(5):251Ц260, 2012.
  605. Negrini S, Pappalardo F, Murdaca G, et al: The antiphospholipid antibody syndrome: from pathophysiology to treatment, Clin Exp Med 17(3):257Ц267, 2017.
  606. Pipe SW, Goldenberg NA: Acquired disorders of hemostasis. In Orkin SH, Fisher DE, Ginsberg D, et al, editors: Nathan and OskiТs hematology of infancy and childhood, ed 8, Philadelphia, 2015, Saunders Elsevier, pp 1103Ц1124.
  607. Hook KM, Abrams CS: The loss of homeostasis in hemostasis: new approaches in treating and understanding acute disseminated intravascular coagulation in critically ill patients, Clin Transl Sci 5(1):85Ц92, 2012.
  608. Levi M, Toh CH, Thachil J, et al: Guidelines for the diagnosis and management of disseminated intravascular coagulation. British committee for standards in haematology, Br J Haematol 145:24Ц33, 2009.
  609. Pipe SW, Goldenberg NA: Acquired disorders of hemostasis. In Orkin SH, Fisher DE, Ginsberg D, et al, editors: Nathan and OskiТs hematology of infancy and childhood, ed 8, Philadelphia, 2015, Saunders Elsevier, pp 1103Ц1124.
  610. Rajagopal R, Thachil J, Monagle P: Disseminated intravascular coagulation in paediatrics, Arch Dis Child 102:187Ц193, 2017.
  611. Thachil J, Toh CH: Current concepts in the management of disseminated intravascular coagulation, Thromb Res 129(Suppl 1):S54ЦS59, 2012.
  612. Boyle S, White RH, Brunson A, et al: Splenectomy and the incidence of venous thromboembolism and sepsis in patients with immune thrombocytopenia, Blood 121(23):4782Ц4790, 2013.
  613. Breakey VR, Blanchette VS: Childhood immune thrombocytopenia: a changing therapeutic landscape, Semin Thromb Hemost 37(7):745Ц755, 2011.
  614. Chaturvedi S, McCrae KR: Treatment of chronic immune thrombocytopenia in children with romiplostim, Lancet 388:4Ц6, 2016.
  615. Cooper N, Bussel JB: The long-term impact of rituximab for childhood immune thrombocytopenia, Curr Rheumatol Rep 12(2):94Ц100, 2010.
  616. Heitink-Poll? KM, Njisten J, Boonacker CW, et al: Clinical and laboratory predictors of chronic immune thrombocytopenia in children: a systematic review and metaanalysis, Blood 124:3295Ц3307, 2015.
  617. Kohne T, Imbach P: Management of children and adolescents with primary immune thrombocytopenia: controversies and solutions, Vox Sang 104(1):55Ц66, 2013.
  618. Mitchell WB, Bussel JB: Thrombopoietin receptor agonists: a critical review, Semin Hematol 52:46Ц52, 2015.
  619. Neunert C, Noroozi N, Norman G, et al: Severe bleeding events in adults and children with primary immune thrombocytopenia: a systematic review, J Thromb Haemost 13:457Ц464, 2015.
  620. Neunert CE, Buchanan GR, Imbach P, et al: Bleeding manifestations and management of children with persistent and chronic immune thrombocytopenia: data from the intercontinental cooperative ITP Study Group (ICIS), Blood 121(22):4457Ц4462, 2013.
  621. Neunert C, Lim W, Crowther M, et al: American society of hematology. The American society of hematology 2011 evidence-based practice guideline for immune thrombocytopenia, Blood 117(16):4190Ц4207, 2011.
  622. OТLeary ST, Glanz JM, McClure DL, et al: The risk of immune thrombocytopenic purpura after vaccination in children and adolescents, Pediatrics 129(2):248Ц255, 2012.
  623. Price V: Auto-immune lymphoproliferative disorder and other secondary immune thrombocytopenias in childhood, Pediatr Blood Cancer 60(Suppl 1):S12ЦS14, 2013.
  624. Psaila B, Cooper N: B-cell depletion in immune thrombocytopenia, Lancet 385:1599Ц1600, 2015.
  625. Psaila B, Petrovic A, Page LK, et al: Intracranial hemorrhage (ICH) in children with immune thrombocytopenic (ITP): study of 40 cases, Blood 114:4777Ц4783, 2009.
  626. Revel-Vilk S, Yacobovich J, Frank S, et al: Age and duration of bleeding symptoms at diagnosis best predict resolution of childhood immune thrombocytopenia at 3,6, and 12 months, J Pediatr 163:1335Ц1339, 2013.
  627. Teachey DT, Lambert MP: Diagnosis and management of autoimmune cytopenias in childhood, Pediatr Clin North Am 60:1489Ц1511, 2013.
  628. Yacobovich J, Revel-Vilk S, Tamary H: Childhood immune thrombocytopenia Ч who will spontaneously recover?, Semin Hematol 50(Suppl 1):S71ЦS74, 2013.
  629. Cuker A: Management of the multiple phases of heparin-induced thrombocytopenia, Thromb Haemost 116:835Ц842, 2016.
  630. Curtis BR: Drug-induced immune thrombocytopenia: incidence, clinical features, laboratory testing, and pathogenic mechanisms, Immunohematology 30:55Ц65, 2014.
  631. Greinacher A: Heparin-induced thrombocytopenia, N Engl J Med 373(13):252Ц260, 2015.
  632. Greinacher A: Clinical practice: heparin-induced thrombocytopenia, N Engl J Med 373:252Ц261, 2015.
  633. Kam T, Alexander M: Drug-induced immune thrombocytopenia, J Pharm Pract 27:430Ц439, 2014.
  634. George JN, Nester CM: Syndromes of thrombotic microangiopathy, N Engl J Med 371(7):654Ц664, 2014.
  635. Kappler S, Ronan-Bentle S, Graham A: Thrombotic microangiopathies (TTP, HUS, HELLP), Hematol Oncol Clin North Am 31:1081Ц1103, 2017.
  636. Loirat C, Coppo P, Veyradier A: Thrombotic thrombocytopenic purpura in children, Curr Opin Pediatr 25:216Ц224, 2013.
  637. Mariotte E, Veyradier A: Thrombotic thrombocytopenic purpura: from diagnosis to therapy, Curr Opin Crit Care 21:593Ц601, 2015.
  638. Ortel TL, Erkan D, Kitchens CS: How I treat catastrophic thrombotic syndromes, Blood 126:1285Ц1293, 2015.
  639. Peyvandi F, Scully M, Kremer-Hovinga JA, et al: Caplacizumab for acquired thrombotic thrombocytopenia purpura, N Engl J Med 374(6):511Ц522, 2016.
  640. Reese JA, Muthurajah DS, Kremer Hovinga JA, et al: Children and adults with thrombotic thrombocytopenic purpura associated with severe, acquired ADAMTS13 deficiency: comparison of incidence, demographic and clinical features, Pediatr Blood Cancer 60:1676Ц1682, 2013.
  641. Sadler JE: Pathophysiology of thrombotic thrombocytopenia purpura, Blood 130(10): 1181, 2017.
  642. Sadler JE, Moake JL, Miyata T, George JN: Recent advances in thrombotic thrombocytopenic purpura, Hematology Am Soc Hematol Educ Program 2004:407Ц423, 2004.
  643. Scully M, Cataland S, Coppo P, et al: Consensus on the standardization of terminology in thrombotic thrombocytopenic purpura and related thrombotic microangiopathies, J Thromb Haemost 15:312Ц322, 2016.
  644. Croteau SE, Gupta D: The clinical spectrum of kaposiform hemangioendothelioma and tufted angioma, Semin Cutan Med Surg 35:147Ц152, 2016.
  645. Drolet BA, Trenor CC 3rd, Brand?o LR, et al: Consensus-derived practice standards plan for complicated kaposiform hemangioendothelioma, J Pediatr 163:285Ц291, 2013.
  646. Albers CA, Newbury-Ecob R, Ouwehand WH, Ghevaert C: New insights into the genetic basis of TAR (thrombocytopenia-absent radii) syndrome, Curr Opin Genet Dev 23:316Ц323, 2013.
  647. Balduini CL, Savoia A: Genetics of familial forms of thrombocytopenia, Hum Genet 131(12):1821Ц1832, 2012.
  648. Geddes AE: Congenital amegakaryocytic thrombocytopenia, Pediatr Blood Cancer 57:199Ц203, 2011.
  649. Worth AJ, Thrasher AJ: Current and emerging treatment options for Wiskott-aldrich syndrome, Expert Rev Clin Immunol 11:1015Ц1032, 2015.
  650. Curtis BR: Recent progress in understanding the pathogenesis of fetal and neonatal alloimmune thrombocytopenia, Br J Haematol 171:671Ц682, 2015.
  651. Peterson JA, McFarland JG, Curtis BR, et al: Neonatal alloimmune thrombocytopenia: pathogenesis, diagnosis and management, Br J Haematol 161(1):3Ц14, 2013.
  652. Mitchell O, Feldman DM, Diakow M, Sigal SH: The pathophysiology of thrombocytopenia in chronic liver disease, Hepat Med 8:39Ц50, 2016.
  653. Tripoi A: Hemostasis abnormalities in cirrhosis, Curr Opin Hematol 22:406Ц412, 2015.
  654. Lassila R: Platelet function tests in bleeding disorders, Semin Thromb Hemost 42:185Ц190, 2016.
  655. Mitchell O, Feldman DM, Diakow M, Sigal SH: The pathophysiology of thrombocytopenia in chronic liver disease, Hepat Med 8:39Ц50, 2016.
  656. Tripoi A: Hemostasis abnormalities in cirrhosis, Curr Opin Hematol 22:406Ц412, 2015.
  657. Blavignac J, Bunimov N, Rivard GE, Hayward CP: Quebec platelet disorder: update on pathogenesis, diagnosis, and treatment, Semin Thromb Hemost 37:713Ц720, 2011.
  658. Gunay-Aygun M, Huizing M, Gahl WA: Molecular defects that affect platelet dense granules, Semin Thromb Hemost 30(5):537Ц547, 2004.
  659. Gunay-Aygun M, Falik-Zaccai TC, Vilboux T, et al: NBEAL2 is mutated in gray platelet syndrome and is required for biogenesis of platelet ?-granules, Nat Genet 43:732Ц734, 2011.
  660. Hinckley J, Di Paola J: Genetic basis of congenital platelet disorders, Hematology Am Soc Hematol Educ Program 2014:337Ц342, 2014.
  661. Lambert MP, Poncz M: Inherited platelet disorders. In Orkin SH, Fisher DE, Ginsberg D, et al, editors: Nathan and OskiТs hematology of infancy and childhood, ed 8, Philadelphia, 2015, Saunders Elsevier, pp 1010Ц1027.
  662. Lambert MP: Update on the inherited platelet disorders, Curr Opin Hematol 22:460Ц466, 2015.
  663. Loredana Asztalos M, Schafernak KT, Gray J, et al: Hermansky-pudlak syndrome: report of two patients with updated genetic classification and management recommendations, Pediatr Dermatol 34(6):638Ц646, 2017.
  664. Monteferrario D, Bolar NA, Marneth AE, et al: A dominant-negative GFI1B mutation in the gray platelet syndrome, N Engl J Med 370(3):245Ц252, 2014.
  665. Nurden AT, Nurden P: Congenital platelet disorders and understanding of platelet function, Br J Haematol 165:165Ц178, 2014.
  666. Quiroga T, Mezzano D: Is my patient a bleeder? A diagnostic framework for mild bleeding disorders, Hematology Am Soc Hematol Educ Program 2012:466Ц474, 2012.
  667. Seward SL Jr, Gahl WA: Hermansky-pudlak syndrome: health care throughout life, Pediatrics 132:153Ц160, 2013.
  668. Amos LE, Carpenter SL, Hoeltzel MF: Lost at sea in search of a diagnosis: a case of unexplained bleeding, Pediatr Blood Cancer 63:1305Ц1306, 2016.
  669. Hickey SE, Varga EA, Kerlin B: Epidemiology of bleeding symptoms and hypermobile Ehlers-danlos syndrome in paediatrics, Haemophilia 22:e490Цe493, 2016.
  670. De Porto AP, Lammers AJ, Bennink RJ, et al: Assessment of splenic function, Eur J Clin Microbiol Infect Dis 29(12):1465Ц1473, 2010.
  671. Hilmes MA, Strouse PJ: The pediatric spleen, Semin Ultrasound CT MR 28:3Ц11, 2007.
  672. Mebius RE, Kraal G: Structure and function of the spleen, Nat Rev Immunol 5(8):606Ц616, 2005.
  673. Nemati M, Hajalioghli P, Jahed S, et al: Normal values of spleen length and volume: an ultrasonographic study in children, Ultrasound Med Biol 42(8):1771Ц1778, 2016.
  674. Rogers ZR, Wang WC, Luo Z, et al: Biomarkers of splenic function in infants with sickle cell anemia: baseline data from the BABY HUG trial, Blood 117(9):2614Ц2617, 2011.
  675. Rousan LA, Fataftah J, Al-Omari MH, et al: Sonographic assessment of liver and spleen size based on age, height, and weight: evaluation of jordanian children, Minerva Pediatr 2015. [Epub ahead of print]
  676. Thapa NB, Shah S, Pradhan A, et al: Sonographic assessment of the normal dimensions of liver, spleen, and kidney in healthy children at tertiary care hospital, Kathmandu Univ Med J (KUMJ) 13(52):286Ц291, 2015.
  677. Ancliff P, Hann I: Splenomegaly. In Sills RH, editor: Practical algorithms in pediatric hematology and oncology, Basel, 2003, Karger.
  678. Baris HN, Cohen IJ, Mistry PK: Gaucher disease: the metabolic defect, pathophysiology, phenotypes and natural history, Pediatr Endocrinol Rev Suppl 1:72Ц81, 2014.
  679. Dabritz J, Worch J, Materna U, et al: Life-threatening hypersplenism due to idiopathic portal hypertension in early childhood: case report and review of the literature, BMC Gastroenterol 10:122, 2010.
  680. Haley K: Congenital hemolytic anemia, Med Clin North Am 101(2):361Ц374, 2017.
  681. Peck-Radosavljevic M: Hypersplenism, Eur J Gastroenterol Hepatol 13(4):317Ц323, 2001.
  682. Perrotta S, Gallagher PG, Mohandas N: Hereditary spherocytosis, Lancet 372(9647): 1411Ц1426, 2008.
  683. Pozo AL, Godfrey EM, Bowles KM: Splenomegaly: investigation, diagnosis and management, Blood Rev 23(3):105Ц111, 2009.
  684. Thomas AS, Mehta AB, Hughes DA: Diagnosing gaucher disease: an on-going need for increased awareness amongst haematologists, Blood Cells Mol Dis 50(3):212Ц217, 2013.
  685. US Department of Health and Human Services, Centers for Disease Control and Prevention: Splenomegaly of unknown etiology in congolese refugees applying for resettlement to the United StatesЧUganda, MMWR 65(35):943Ц944, 2015.
  686. Weinreb NJ, Rosenbloom BE: Splenomegaly, hypersplenism, and hereditary disorders with splenomegaly, O J Gen 3:24Ц43, 2013
  687. Alexakis N, Dardamanis D, Albanopoulos K, et al: Incidence, risk factors, and outcome of portal vein thrombosis after laparoscopic-assisted splenectomy in beta-thalassemia patients: a prospective exploratory study, J Laparoendosc Adv Surg Tech A 23(2):123Ц128, 2013.
  688. Audia S, Santegoets K, Laarhoven AG, et al: Fc? receptor expression on splenic macrophages in adult immune thrombocytopenia, Clin Exp Immunol 188(2):275Ц282, 2017.
  689. Daodu O, Brindle M, Alvarez-Allende CR, et al: Outcomes of an accelerated care pathway for pediatric blunt solid organ injuries in a public healthcare system, J Pediatr Surg 52(5):826Ц831, 2017.
  690. Das A, Bansal D, Ahluwalia J, et al: Risk factors for thromboembolism and pulmonary artery hypertension following splenectomy in children with hereditary spherocytosis, Pediatr Blood Cancer 61(1):29Ц33, 2014.
  691. De Porto APNA, Lammers AJJ, Bennink RJ: Assessment of splenic function, Eur J Clin Microbiol Infect Dis 29:1465Ц1473, 2010.
  692. Di Sabatino A, Carsetti R, Corazza GR: Post-splenectomy and hyposplenic states, Lancet 378(9785):86Ц97, 2011.
  693. Erdem SB, Genel F, Erdur B, et al: Asplenia in children with congenital heart disease as a cause of poor outcome, Cent Eur J Immunol 40(2):266Ц269, 2015.
  694. Frey MK, Alias S, Winter MP, et al: Splenectomy is modifying the vascular remodeling of thrombosis, J Am Heart Assoc 3(1):e000772, 2014.
  695. Kimberlin DW: Pneumococcal infections. In Red book: 2015 report of the committee on infectious diseases, ed 30, Elk Grove Village, IL, 2015, American Academy of Pediatrics.
  696. Kimmig LM, Palevsky HI: Review of the association between splenectomy and chronic thromboembolic pulmonary hypertension, Ann Am Thorac Soc 13(6):945Ц954, 2016.
  697. Linnaus ME, Langlais CS, Garcia NM, et al: Failure of nonoperative management of pediatric blunt liver and spleen injuries: a prospective Arizona-Texas-OklahomaMemphis-Arkansas Consortium study, J Trauma Acute Care Surg 82(4):672Ц679, 2017.
  698. Nuorti JP, Whitney CG, Centers for Disease Control and Prevention (CDC): Prevention of pneumococcal disease among infants and children: use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccineЧrecommendations of the advisory committee on immunization practices (ACIP), MMWR Recomm Rep 59:1, 2010.
  699. Palkar AV, Agrawal A, Verma S, et al: Post splenectomy related pulmonary hypertension, World J Respirol 5(2):69Ц77, 2015.
  700. Piano Mortari E, Baban A, Cantarutti N, et al: Heterotaxy syndrome with and without spleen: different infection risk and management, J Allergy Clin Immunol 139(6):1981Ц1984, 2017.
  701. Rice HE, Crary SE, Langer JC, et al: Comparative effectiveness of different types of splenectomy for children with congenital hemolytic anemias, J Pediatr 160(4):684Ц689.e13, 2012.
  702. Rubin LG, Schaffner W: Care of the asplenic patient, N Engl J Med 371:349Ц356, 2014.
  703. Theilacker C, Ludewig K, Serr A, et al: Splenectomy, Pneumococcus, and fulminant infection SPLEEN OFF study group: overwhelming postsplenectomy infection: a prospective multicenter cohort study, Clin Infect Dis 62(7):871Ц878, 2016.
  704. Klotz L, Norman S, Vieira JM: Cardiac lymphatics are heterogeneous in origin and respond to injury, Nature 522:62Ц67, 2015.
  705. Louveau A, Smirnov I, Keyes TJ, et al: Structural and functional features of central nervous system lymphatic vessels, Nature 523:337Ц341, 2015.
  706. Semo J, Nicenbiom J, Yaniv K: Development of the lymphatic system: new questions and paradigms, Development 143:924Ц935, 2016.
  707. Yang Y, Guillermo O: Development of the mammalian vasculature, J Clin Invest 124:888Ц897, 2014.
  708. Adams DM, Trenor CC III, Hammill AM, et al: Efficacy and safety of sirolimus in the treatment of complicated vascular anomalies, Pediatrics 137(2):e201153257, 2016.
  709. Bagrodia N, Defnet AM, Kandel JJ: Management of lymphatic malformations in children, Curr Opin Pediatr 27:356Ц363, 2015.
  710. Brouillard P, Boon L, Vikkula M: Genetics of lymphatic anomalies, J Clin Invest 124(3):898Ц904, 2014.
  711. Dentici ML, Di Pede A, Lepri FR, et al: Kabuki syndrome: clinical and molecular diagnosis in the first year of life, Arch Dis Child 100:158Ц164, 2015.
  712. Frosk P, Chodirker B, Simard L, et al: A novel CCBE1 mutation leading to a mild form of hennekam syndrome: case report and review of the literature, BMC Med Genet 16:28, 2015.
  713. Garcia-Montero P, del Boz J, Sanchez-Martinez M, et al: Microcystic lymphatic malformation successfully treated with topical rapamycin, Pediatrics 139(5):e20162105, 2016.
  714. Luks VL, Kamitaki N, Vivero MP, et al: Lymphatic and other malformative/overgrowth disorders are caused by somatic mutations in PIK3CA, J Pediatr 166:1048Ц1054, 2015.
  715. Maclellan RA, Greene AK: Lymphedema, Semin Pediatr Surg 23:191Ц197, 2014.
  716. Trenor CC II, Chaudry G: Complex lymphatic anomalies, Semin Pediatr Surg 23:186Ц190, 2014.
  717. Vlahovic AM, Vlahovic NS, Haxhija EQ: Sirolimus for the treatment of a massive capillary-lymphatico-venous malformation: a case report, Pediatrics 136(2):e513Ц e516, 2015.
  718. Bozlak S, Varkal MA, Yildiz I, et al: Cervical lymphadenopathies in children: a prospective cohort study, Int J Pediatr Otorhinolaryngol 82:81Ц87, 2016.
  719. Gov-Ari E, Hopewell BL: Correlation between pre-operative diagnosis and post-operative pathology reading in pediatric neck masses: a review of 281 cases, Int J Pediatr Otorhinolaryngol 79:2Ц7, 2015.
  720. Lee DY, Seok J, Kim Y, et al: Neck computed tomography in pediatric neck mass as initial evaluation in ED: is it malpractice, Am J Emerg Med 32(10):1237Ц1240, 2014.
  721. Locke R, Comfort R, Kubba H: When does an enlarged cervical lymph node in a child need excision? A systematic review, Int J Pediatr Otorhinolaryngol 78:393Ц401, 2014.
  722. Penn EB Jr, Goudy SL: Pediatric inflammatory adenopathy, Otolaryngol Clin North Am 48:137Ц151, 2015.
  723. Pynnonen MA, Gillespie MB, Roman B, et al: Clinical practice guideline: evaluation of the neck mass in adults, Otolaryngol Head Neck Surg 157(2S):S1ЦS30, 2017.
  724. Sahai S: Lymphadenopathy, Pediatr Rev 34(5):216Ц227, 2013.
  725. Cuglievan B, Miranda RN: Kikuchi-fujimoto disease, Blood 129(7):917, 2017.
  726. Dumas G, Prendki V, Haroche J, et al: Kikuchi-fujimoto disease, Medicine (Baltimore) 93(24):372Ц380, 2014.
  727. Kang HM, Kim JY, Choi EH, et al: Clinical characteristics of severe histiocytic necrotizing lymphadenitis (kikuchi-fujimoto disease) in children, J Pediatr 171:208Ц212, 2016.
  728. Kim JY, Lee H, Yun BL: Ultrasonographic findings of kikuchi cervical lymphadenopathy in children, Ultrasonography 36(1):66Ц70, 2017.
  729. Cooper SL, Arceci RJ, Gamper CJ, et al: Successful treatment of recurrent autoimmune cytopenias in the context of sinus histiocytosis with massive lymphadenopathy using sirolimus, Pediatr Blood Cancer 63:358Ц360, 2016.
  730. Emile JF, Abla O, Fraitag S, et al: Revised classification of histiocytoses and neoplasms of the macrophageЦdendritic cell lineages, Blood 127(22):2672Ц2681, 2016.
  731. Haroche J, Abla O: Uncommon histiocytic disorders: Rosai-dorfman, juvenile xanthogranuloma, and Erdheim-chester disease, Hematology Am Soc Hematol Educ Program 2015:571Ц578, 2015.
  732. Simko SJ, Tran HD, Jones J, et al: Clofarabine salvage therapy in refractory multifocal histiocytic disorders, including langerhans cell histiocytosis, juvenile xanthogranuloma and Rosai-dorfman disease, Pediatr Blood Cancer 61:479Ц487, 2014.
  733. Fajgenbaum DC, Uldrick TS, Bagg A, et al: International, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric castleman disease, Blood 129(12):1646Ц1657, 2017.
  734. Fajgenbaum DC, van Rhee F, Nabel CS: HHV-8-negative, idiopathic multicentric castleman disease: novel insights into biology, pathogenesis, and therapy, Blood 123(19):2924Ц2933, 2014.
  735. Jain P, Verstovsek S, Loghavi S, et al: Durable remission with rituximab in a patient with an unusual variant of CastlemanТs disease with myelofibrosis: TAFRO syndrome, Am J Hematol 90(11):1091Ц1092, 2015.
  736. Liu AY, Nabel CS, Finkelman BS, et al: Idiopathic multicentric CastlemanТs disease: a systematic literature review, Lancet Hematol 3(4):e163Цe175, 2016.
  737. Sbihi Z, Dossier A, Boutboul D, et al: INKT and memory B-cell alterations in HHV-8 multicentric castleman disease, Blood 129(7):855Ц865, 2017.
  738. Smith C, Lee-Miller C, Dishop MK, et al: Multicentric castleman disease presenting with fever, J Pediatr 165:1261Ц1265, 2014.
  739. Turcotte LM, Correll CK, Reed RC, et al: Sustained remission of severe multicentric castleman disease following multiagent chemotherapy and tocilizumab maintenance, Pediatr Blood Cancer 61:737Ц739, 2014.

“руды отечественных авторов при подготовке статей по педиатрии дл€ пользователей сайта - не использовались, так как их вы всегда можете найти в библиотеках.

- ¬ернутьс€ в раздел "ѕедиатри€"

–едактор: »скандер ћилевски. ƒата обновлени€ публикации: 24.5.2024

ћедунивер ћы в Telegram ћы в YouTube ћы в VK ‘орум консультаций врачей  онтакты, реклама
»нформаци€ на сайте подлежит консультации лечащим врачом и не замен€ет очной консультации с ним.
—м. подробнее в пользовательском соглашении.